QUARTERLY REPORT

Q1 2023 — Form 10-Q

Q1 2023PDF · 42 pages456 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________________________________
FORM 10-Q
________________________________________________________
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the quarterly period ended March 31, 2023
OR
☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 001-08089
DANAHER CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 59-1995548
(State of Incorporation) (I.R.S. Employer Identification Number)
2200 Pennsylvania Avenue, N.W., Suite 800W 20037-1701
Washington, DC
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: 202-828-0850
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, $0.01 par value DHR New York Stock Exchange
5.00% Mandatory Convertible Preferred Stock,
Series B, without par value DHR.PRB New York Stock Exchange
1.700% Senior Notes due 2024 DHR 24 New York Stock Exchange
0.200% Senior Notes due 2026 DHR/26 New York Stock Exchange
2.100% Senior Notes due 2026 DHR 26 New York Stock Exchange
1.200% Senior Notes due 2027 DHR/27 New York Stock Exchange
0.450% Senior Notes due 2028 DHR/28 New York Stock Exchange
2.500% Senior Notes due 2030 DHR 30 New York Stock Exchange
0.750% Senior Notes due 2031 DHR/31 New York Stock Exchange
1.350% Senior Notes due 2039 DHR/39 New York Stock Exchange
1.800% Senior Notes due 2049 DHR/49 New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to
file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

-- 1 of 42 --

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller
reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer ☒ Accelerated Filer ☐
Non-accelerated Filer ☐ Smaller Reporting Company ☐
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act) Yes ☐ No ☒
The number of shares of common stock outstanding at April 20, 2023 was 737,898,789.

-- 2 of 42 --

DANAHER CORPORATION
INDEX
FORM 10-Q
Page
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Condensed Balance Sheets 1
Consolidated Condensed Statements of Earnings 2
Consolidated Condensed Statements of Comprehensive Income 3
Consolidated Condensed Statements of Stockholders’ Equity 4
Consolidated Condensed Statements of Cash Flows 5
Notes to Consolidated Condensed Financial Statements 6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20
Item 3. Quantitative and Qualitative Disclosures About Market Risk 35
Item 4. Controls and Procedures 36
PART II - OTHER INFORMATION
Item 1. Legal Proceedings 37
Item 1A. Risk Factors 37
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 37
Item 5. Other Information 37
Item 6. Exhibits 38
Signatures 39

-- 3 of 42 --

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
($ in millions, except per share amount)
(unaudited)
March 31, 2023 December 31, 2022
ASSETS
Current assets:
Cash and equivalents $ 7,379 $ 5,995
Trade accounts receivable, less allowance for doubtful accounts of $125 and $126,
respectively 4,313 4,918
Inventories:
Finished goods 1,620 1,504
Work in process 542 473
Raw materials 1,221 1,133
Total inventories 3,383 3,110
Prepaid expenses and other current assets 1,457 1,860
Total current assets 16,532 15,883
Property, plant and equipment, net of accumulated depreciation of $4,022 and $3,893,
respectively 4,065 3,956
Other long-term assets 4,611 4,459
Goodwill 39,856 39,752
Other intangible assets, net 19,976 20,300
Total assets $ 85,040 $ 84,350
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Notes payable and current portion of long-term debt $ 1,571 $ 591
Trade accounts payable 2,081 2,296
Accrued expenses and other liabilities 5,078 5,502
Total current liabilities 8,730 8,389
Other long-term liabilities 6,563 6,785
Long-term debt 18,261 19,086
Stockholders’ equity:
Preferred stock, no par value, 15.0 million shares authorized; 1.72 million shares of
5.00% Mandatory Convertible Preferred Stock, Series B, issued and outstanding as of
March 31, 2023 and December 31, 2022 1,668 1,668
Common stock - $0.01 par value, 2.0 billion shares authorized; 870.4 million issued
and 729.2 million outstanding as of March 31, 2023; 869.3 million issued and 728.3
million outstanding as of December 31, 2022 9 9
Additional paid-in capital 12,130 12,072
Retained earnings 40,437 39,205
Accumulated other comprehensive income (loss) (2,766) (2,872)
Total Danaher stockholders’ equity 51,478 50,082
Noncontrolling interests 8 8
Total stockholders’ equity 51,486 50,090
Total liabilities and stockholders’ equity $ 85,040 $ 84,350
See the accompanying Notes to the Consolidated Condensed Financial Statements.
Table of Contents
1

-- 4 of 42 --

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
($ and shares in millions, except per share amounts)
(unaudited)
Three-Month Period Ended
March 31, 2023 April 1, 2022
Sales $ 7,167 $ 7,688
Cost of sales (2,797) (2,983)
Gross profit 4,370 4,705
Operating costs:
Selling, general and administrative expenses (2,147) (2,092)
Research and development expenses (429) (441)
Operating profit 1,794 2,172
Nonoperating income (expense):
Other income (expense), net 24 (20)
Interest expense (68) (54)
Interest income 48 1
Earnings before income taxes 1,798 2,099
Income taxes (348) (374)
Net earnings 1,450 1,725
Mandatory convertible preferred stock dividends (21) (41)
Net earnings attributable to common stockholders $ 1,429 $ 1,684
Net earnings per common share:
Basic $ 1.96 $ 2.35
Diluted $ 1.94 $ 2.31
Average common stock and common equivalent shares outstanding:
Basic 729.4 716.3
Diluted 737.2 737.7
See the accompanying Notes to the Consolidated Condensed Financial Statements.
Table of Contents
2

-- 5 of 42 --

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME
($ in millions)
(unaudited)
Three-Month Period Ended
March 31, 2023 April 1, 2022
Net earnings $ 1,450 $ 1,725
Other comprehensive income (loss), net of income taxes:
Foreign currency translation adjustments 25 (343)
Pension and postretirement plan benefit adjustments — 14
Cash flow hedge adjustments 81 (20)
Total other comprehensive income (loss), net of income taxes 106 (349)
Comprehensive income $ 1,556 $ 1,376
See the accompanying Notes to the Consolidated Condensed Financial Statements.
Table of Contents
3

-- 6 of 42 --

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY
($ in millions)
(unaudited)
Three-Month Period Ended
March 31, 2023 April 1, 2022
Preferred stock:
Balance, beginning and end of period $ 1,668 $ 3,268
Common stock:
Balance, beginning and end of period $ 9 $ 9
Additional paid-in capital:
Balance, beginning of period $ 12,072 $ 10,090
Common stock-based award 58 48
Acquisition of noncontrolling interests — (15)
Balance, end of period $ 12,130 $ 10,123
Retained earnings:
Balance, beginning of period $ 39,205 $ 32,827
Net earnings 1,450 1,725
Common stock dividends declared (197) (179)
Mandatory Convertible Preferred Stock dividends declared (21) (41)
Balance, end of period $ 40,437 $ 34,332
Accumulated other comprehensive income (loss):
Balance, beginning of period $ (2,872) $ (1,027)
Other comprehensive income (loss) 106 (349)
Balance, end of period $ (2,766) $ (1,376)
Noncontrolling interests:
Balance, beginning of period $ 8 $ 10
Change in noncontrolling interests — (4)
Balance, end of period $ 8 $ 6
Total stockholders’ equity, end of period $ 51,486 $ 46,362
See the accompanying Notes to the Consolidated Condensed Financial Statements.
Table of Contents
4

-- 7 of 42 --

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
($ in millions)
(unaudited)
Three-Month Period Ended
March 31, 2023 April 1, 2022
Cash flows from operating activities:
Net earnings $ 1,450 $ 1,725
Noncash items:
Depreciation 173 179
Amortization of intangible assets 384 386
Stock-based compensation expense 79 80
Investment (gains) losses (22) 24
Change in trade accounts receivable, net 631 80
Change in inventories (257) (431)
Change in trade accounts payable (228) (131)
Change in prepaid expenses and other assets 30 (22)
Change in accrued expenses and other liabilities (293) 78
Net cash provided by operating activities 1,947 1,968
Cash flows from investing activities:
Cash paid for acquisitions — (17)
Payments for additions to property, plant and equipment (275) (250)
Proceeds from sales of property, plant and equipment — 2
Payments for purchases of investments (43) (274)
Proceeds from sales of investments 1 17
All other investing activities 13 19
Total cash used in investing activities (304) (503)
Cash flows from financing activities:
Payments for the issuance of common stock in connection with stock-based
compensation, net (34) (46)
Payment of dividends (204) (191)
Net (repayments of) proceeds from borrowings (maturities of 90 days or less) (4) 10
All other financing activities (20) (47)
Total cash used in financing activities (262) (274)
Effect of exchange rate changes on cash and equivalents 3 (60)
Net change in cash and equivalents 1,384 1,131
Beginning balance of cash and equivalents 5,995 2,586
Ending balance of cash and equivalents $ 7,379 $ 3,717
Supplemental disclosures:
Cash interest payments $ 82 $ 84
Cash income tax payments 228 227
See the accompanying Notes to the Consolidated Condensed Financial Statements.
Table of Contents
5

-- 8 of 42 --

DANAHER CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(unaudited)
NOTE 1. GENERAL
The Consolidated Condensed Financial Statements included herein have been prepared by Danaher Corporation (“Danaher” or
the “Company”) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). In
this quarterly report, the terms “Danaher” or the “Company” refer to Danaher Corporation, Danaher Corporation and its
consolidated subsidiaries, or the consolidated subsidiaries of Danaher Corporation, as the context requires. Certain information
and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally
accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to SEC rules and regulations; however,
the Company believes that the disclosures are adequate to make the information presented not misleading. The Consolidated
Condensed Financial Statements included herein should be read in conjunction with the financial statements as of and for the
year ended December 31, 2022 and the Notes thereto included in the Company’s 2022 Annual Report on Form 10-K filed on
February 22, 2023 (the “2022 Annual Report”).
In the opinion of the Company, the accompanying financial statements contain all adjustments (consisting of only normal
recurring accruals) necessary to present fairly the financial position of the Company as of March 31, 2023 and December 31,
2022, its results of operations for the three-month periods ended March 31, 2023 and April 1, 2022 and its cash flows for each
of the three-month periods then ended.
There have been no changes to the Company’s significant accounting policies described in the Company’s 2022 Annual Report
that have a material impact on the Company’s Consolidated Condensed Financial Statements and the related Notes.
Reclassifications of certain prior year amounts have been made to conform to the current year presentation.
Operating Leases—As of March 31, 2023 and December 31, 2022, operating lease right-of-use assets where the Company was
the lessee were approximately $1.1 billion and $1.0 billion, respectively, and are included within other long-term assets in the
accompanying Consolidated Condensed Balance Sheets. The associated operating lease liabilities were approximately $1.1
billion as of both March 31, 2023 and December 31, 2022 and are included in accrued expenses and other liabilities and other
long-term liabilities.
NOTE 2. VERALTO CORPORATION SEPARATION
In September 2022, the Company announced its intention to separate its Environmental & Applied Solutions business into a
publicly traded company, to be known as Veralto Corporation (“Veralto”). The Environmental & Applied Solutions business
had sales for the year ended December 31, 2022 of approximately $4.8 billion. The transaction is expected to be tax-free to the
Company’s shareholders. The Company is targeting to complete the planned separation of the Environmental & Applied
Solutions business in the fourth quarter of 2023, subject to the satisfaction of certain conditions, including obtaining final
approval from the Danaher Board of Directors, satisfactory completion of financing, receipt of tax opinions, receipt of favorable
rulings from the Internal Revenue Service (“IRS”) and receipt of other regulatory approvals. Until the completion of the
planned separation, the Environmental & Applied Solutions business will be reported as continuing operations.
The Company incurred separation costs of $28 million ($25 million after-tax) related to preparation for the anticipated
separation of the Company’s Environmental & Applied Solutions business primarily related to professional fees for legal, tax,
finance and information technology services and duplicative general and administrative costs in the three-month period ended
March 31, 2023.
NOTE 3. NET EARNINGS PER COMMON SHARE
Basic net earnings per common share (“EPS”) is calculated by taking net earnings less the Mandatory Convertible Preferred
Stock (“MCPS”) dividends divided by the weighted average number of common shares outstanding for the applicable period.
Diluted net EPS is computed by taking net earnings less the MCPS dividends divided by the weighted average number of
common shares outstanding increased by the number of additional shares that would have been outstanding had the potentially
dilutive common shares been issued and reduced by the number of shares the Company could have repurchased with the
proceeds from the issuance of the potentially dilutive shares. For the three-month periods ended March 31, 2023 and April 1,
2022, approximately 2.4 million and 418 thousand options, respectively, to purchase shares were excluded from the diluted EPS
calculation, as the impact of their inclusion would have been anti-dilutive.
Table of Contents
6

-- 9 of 42 --

The impact of the MCPS Series B calculated under the if-converted method was anti-dilutive for the three-month periods ended
March 31, 2023 and April 1, 2022, and as such 8.6 million shares underlying the MCPS Series B were excluded from the
calculation of diluted EPS in both periods and the related MCPS Series B dividends of $21 million were included in the
calculation of net earnings for diluted EPS for the periods. As of April 17, 2023, all outstanding shares of the MCPS Series B
converted into 8.6 million shares of the Company’s common stock.
The impact of the MCPS Series A calculated under the if-converted method was dilutive for the three-month period ended
April 1, 2022, and as such 11.0 million shares underlying the MCPS Series A were included in the calculation of diluted EPS in
the three-month period and the related MCPS Series A dividends of $20 million were excluded from the calculation of net
earnings for diluted EPS. On April 15, 2022, all outstanding shares of the MCPS Series A converted into 11.0 million shares of
the Company’s common stock. Refer to Note 14 for additional information about the MCPS Series A and B conversions.
Information related to the calculation of net earnings per common share is summarized as follows ($ and shares in millions,
except per share amounts):
Three-Month Period Ended
March 31, 2023 April 1, 2022
Numerator:
Net earnings $ 1,450 $ 1,725
MCPS dividends (21) (41)
Net earnings attributable to common stockholders for Basic EPS 1,429 1,684
Adjustment for MCPS dividends for dilutive MCPS — 20
Net earnings attributable to common stockholders after assumed conversions for Diluted
EPS $ 1,429 $ 1,704
Denominator:
Weighted average common shares outstanding used in Basic EPS 729.4 716.3
Incremental common shares from:
Assumed exercise of dilutive options and vesting of dilutive restricted stock units
(“RSUs”) and performance stock units (“PSUs”) 7.8 10.4
Weighted average MCPS converted shares — 11.0
Weighted average common shares outstanding used in Diluted EPS 737.2 737.7
Basic EPS $ 1.96 $ 2.35
Diluted EPS $ 1.94 $ 2.31
Table of Contents
7

-- 10 of 42 --

NOTE 4. REVENUE
The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three-
month periods ended March 31, 2023 and April 1, 2022 ($ in millions). Sales taxes and other usage-based taxes collected from
customers are excluded from revenue.
Biotechnology Life Sciences Diagnostics
Environmental
& Applied
Solutions Total
For the Three-Month Period Ended
March 31, 2023:
Geographical region:
North America(a) $ 618 $ 708 $ 1,124 $ 572 $ 3,022
Western Europe 647 364 420 277 1,708
Other developed markets 79 128 117 29 353
High-growth markets(b) 520 509 715 340 2,084
Total $ 1,864 $ 1,709 $ 2,376 $ 1,218 $ 7,167
Revenue type:
Recurring $ 1,511 $ 1,039 $ 2,112 $ 724 $ 5,386
Nonrecurring 353 670 264 494 1,781
Total $ 1,864 $ 1,709 $ 2,376 $ 1,218 $ 7,167
For the Three-Month Period Ended
April 1, 2022:
Geographical region:
North America(a) $ 782 $ 738 $ 1,306 $ 528 $ 3,354
Western Europe 707 328 524 269 1,828
Other developed markets 85 137 124 32 378
High-growth markets(b) 642 463 690 333 2,128
Total $ 2,216 $ 1,666 $ 2,644 $ 1,162 $ 7,688
Revenue type:
Recurring $ 1,801 $ 1,037 $ 2,370 $ 690 $ 5,898
Nonrecurring 415 629 274 472 1,790
Total $ 2,216 $ 1,666 $ 2,644 $ 1,162 $ 7,688
(a) The Company defines North America as the United States and Canada.
(b) The Company defines high-growth markets as developing markets of the world experiencing extended periods of accelerated growth in
gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America (including Mexico) and
Asia (with the exception of Japan, Australia and New Zealand). The Company defines developed markets as all markets of the world that
are not high-growth markets.
The Company sells equipment to customers as well as consumables and services, some of which customers purchase on a
recurring basis. Consumables sold for use with the equipment sold by the Company are typically critical to the use of the
equipment and are typically used on a one-time or limited basis, requiring frequent replacement in the customer’s operating
cycle. Examples of these consumables include reagents used in diagnostic tests, chromatography resins used for research and
bioprocessing, filters used in filtration, separation and purification processes and cartridges for marking and coding equipment.
Additionally, some of the Company’s consumables are used on a standalone basis, such as water treatment solutions, custom
nucleic acids and genomics solutions. The Company separates its goods and services between those typically sold to a
customer on a recurring basis and those typically sold to a customer on a nonrecurring basis. Recurring revenue includes
revenue from consumables, services and operating-type leases (“OTLs”). Nonrecurring revenue includes sales of equipment
and sales-type leases (“STLs”). OTLs and STLs are included in the above revenue amounts. For the three-month periods
ended March 31, 2023 and April 1, 2022, lease revenue was $120 million and $124 million, respectively.
Table of Contents
8

-- 11 of 42 --

Remaining performance obligations related to Topic 606, Revenue from Contracts with Customers, represent the aggregate
transaction price allocated to performance obligations with an original contract term greater than one year which are fully or
partially unsatisfied at the end of the period. As of March 31, 2023, the aggregate amount of the transaction price allocated to
remaining performance obligations was approximately $4.9 billion. The Company expects to recognize revenue on
approximately 57% of the remaining performance obligations over the next 12 months, 25% over the subsequent 12 months,
and the remainder recognized thereafter.
The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables
(“contract assets”) and deferred revenue, customer deposits and billings in excess of revenue recognized (“contract liabilities”)
on the Consolidated Condensed Balance Sheets.
Most of the Company’s long-term contracts are billed as work progresses in accordance with the contract terms and conditions,
either at periodic intervals or upon achievement of certain milestones. Often this results in billing occurring subsequent to
revenue recognition resulting in contract assets. Contract assets are generally classified as other current assets in the
Consolidated Condensed Balance Sheets. The balance of contract assets as of March 31, 2023 and December 31, 2022 was $84
million and $90 million, respectively.
The Company often receives cash payments from customers in advance of the Company’s performance resulting in contract
liabilities that are classified as either current or long-term in the Consolidated Condensed Balance Sheets based on the timing of
when the Company expects to recognize revenue. As of March 31, 2023 and December 31, 2022, contract liabilities were
approximately $2.0 billion and $1.9 billion, respectively, and are included within accrued expenses and other liabilities and
other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. The increase in the contract liability
balance during the three-month period ended March 31, 2023 was primarily a result of cash payments received in advance of
satisfying performance obligations, partially offset by revenue recognized during the period that was included in the opening
contract liability balance. Revenue recognized during the three-month periods ended March 31, 2023 and April 1, 2022 that
was included in the contract liability balance on December 31, 2022 and December 31, 2021 was $686 million and
$662 million, respectively. Contract assets and liabilities are reported on a net basis on the accompanying Consolidated
Condensed Balance Sheets on a contract-by-contract basis at the end of each reporting period.
NOTE 5. SEGMENT INFORMATION
The Company operates and reports its results in four separate business segments consisting of the Biotechnology, Life Sciences,
Diagnostics, and Environmental & Applied Solutions segments. When determining the reportable segments, the
Company aggregated operating segments based on their similar economic and operating characteristics. Operating profit
represents total revenues less operating expenses, excluding nonoperating income and expense, interest and income taxes.
Operating profit amounts in the Other segment consist of unallocated corporate costs and other costs not considered part of
management’s evaluation of reportable segment operating performance. Intersegment amounts are not significant and are
eliminated to arrive at consolidated totals.
Segment results are shown below ($ in millions):
Three-Month Period Ended
March 31, 2023 April 1, 2022
Sales:
Biotechnology $ 1,864 $ 2,216
Life Sciences 1,709 1,666
Diagnostics 2,376 2,644
Environmental & Applied Solutions 1,218 1,162
Total $ 7,167 $ 7,688
Operating profit:
Biotechnology $ 596 $ 800
Life Sciences 321 318
Diagnostics 677 886
Environmental & Applied Solutions 299 236
Other (99) (68)
Total $ 1,794 $ 2,172
Table of Contents
9

-- 12 of 42 --

NOTE 6. INCOME TAXES
The following table summarizes the Company’s effective tax rate:
Three-Month Period Ended
March 31, 2023 April 1, 2022
Effective tax rate 19.4 % 17.8 %
The Company operates globally, including in certain jurisdictions with lower tax rates than the United States (“U.S.”) federal
statutory rate. Therefore, the impact of operating in such jurisdictions contributes to a lower effective tax rate compared to the
U.S. federal statutory tax rate.
The effective tax rate for the three-month period ended March 31, 2023 differs from the U.S. federal statutory rate of 21.0%
principally due the geographic mix of earnings described above and net discrete benefits of $5 million related primarily to
excess tax benefits from stock-based compensation and the release of reserves for uncertain tax positions due to the expiration
of statutes of limitation, partially offset by tax costs related to the planned separation of the Environmental & Applied Solutions
business and changes in estimates associated with prior period uncertain tax positions. The net discrete benefits reduced the
effective tax rate by 0.3% for the three-month period ended March 31, 2023.
The effective tax rate for the three-month period ended April 1, 2022 differs from the U.S. federal statutory rate of 21.0%
principally due to net discrete benefits of $41 million related primarily to excess tax benefits from stock-based compensation
and changes in estimates associated with prior period uncertain tax positions. These factors reduced the effective tax rate by
2.0% for the three-month period ended April 1, 2022.
In the fourth quarter of 2022, the IRS proposed significant adjustments to the Company’s taxable income for the years 2016
through 2018 with respect to the deferral of tax on certain premium income related to the Company’s self-insurance programs.
For income tax purposes, the recognition of premium income has been deferred in accordance with U.S. tax laws related to
insurance. The IRS challenged the deferral of premium income for certain types of the Company’s self-insurance policies. The
proposed adjustments would have increased the Company’s taxable income over the 2016 through 2018 periods by
approximately $2.5 billion. In the first quarter of 2023, the Company settled these proposed adjustments with the IRS, although
the audit is still open with respect to other matters for the 2016 through 2018 period. The impact of the settlement with respect
to the Company’s self-insurance policies was not material to the Company’s financial statements, including cash flows and the
effective tax rate. As the settlement with the IRS was specific to the audit period, the settlement does not preclude the IRS from
proposing similar adjustments to the Company’s self-insurance programs with respect to periods subsequent to 2018.
Management believes the positions the Company has taken in its U.S. tax returns are in accordance with the relevant tax laws.
For a description of the Company’s significant tax matters, reference is made to the financial statements as of and for the year
ended December 31, 2022 and Note 7 thereto included in the Company’s 2022 Annual Report.
NOTE 7. OTHER INCOME (EXPENSE), NET
The following sets forth the components of the Company’s other income (expense), net ($ in millions):
Three-Month Period Ended
March 31, 2023 April 1, 2022
Other components of net periodic benefit costs $ 2 $ 4
Investment gains (losses):
Realized investment gains (losses) — 37
Unrealized investment gains (losses) 22 (61)
Total investment gains (losses) 22 (24)
Total other income (expense), net $ 24 $ (20)
Other Components of Net Periodic Benefit Costs
The Company disaggregates the service cost component of net periodic benefit costs of noncontributory defined benefit pension
plans and other postretirement employee benefit plans and presents the other components of net periodic benefit costs in other
income (expense), net. These other components of net periodic benefit costs include the assumed rate of return on plan assets,
partially offset by amortization of actuarial losses and interest. The Company’s net periodic benefit costs for the three-month
period ended April 1, 2022 included a settlement loss of $10 million ($9 million after-tax) as a result of the transfer of a portion
of its non-U.S. pension liabilities related to one defined benefit plan to a third-party.
Table of Contents
10

-- 13 of 42 --

Investment Gains (Losses)
The Company estimates the fair value of its investments in equity securities using the Fair Value Alternative and records
adjustments to fair value within net earnings. Additionally, the Company is a limited partner in partnerships that invest
primarily in early-stage companies. While the partnerships record these investments at fair value, the Company’s investments
in the partnerships are accounted for under the equity method of accounting. The investment gains (losses) include realized and
unrealized gains and losses related to changes in the fair value of the Company’s investments in equity securities and the
Company’s equity in earnings of the partnerships that reflect the changes in fair value of the investments of the partnerships,
and related management fees and operating expenses.
NOTE 8. GOODWILL AND OTHER INTANGIBLE ASSETS
The following is a rollforward of the Company’s goodwill ($ in millions):
Balance, December 31, 2022 $ 39,752
Adjustments due to finalization of purchase price allocations (4)
Foreign currency translation and other 108
Balance, March 31, 2023 $ 39,856
The carrying value of goodwill by segment is summarized as follows ($ in millions):
March 31, 2023 December 31, 2022
Biotechnology $ 22,167 $ 22,087
Life Sciences 8,319 8,314
Diagnostics 6,883 6,875
Environmental & Applied Solutions 2,487 2,476
Total $ 39,856 $ 39,752
The Company has not identified any “triggering” events which indicate an impairment of goodwill in the first quarter of 2023.
The Company reviews identified intangible assets for impairment whenever events or changes in circumstances indicate that the
related carrying amounts may not be recoverable. The Company has not identified any impairment triggers which resulted in
impairments of intangible assets in the first quarter of 2023.
NOTE 9. FAIR VALUE MEASUREMENTS
Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where the
Company’s assets and liabilities are required to be carried at fair value and provide for certain disclosures related to the
valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes
the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets
or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or
similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates,
yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through
correlation. Level 3 inputs are unobservable inputs based on the Company’s assumptions. A financial asset or liability’s
classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement
in its entirety.
A summary of financial assets that are measured at fair value on a recurring basis were as follows ($ in millions):
Balance Quoted Prices in Active
Market (Level 1) Significant Other
Observable Inputs (Level 2) Significant Unobservable
Inputs (Level 3)
March 31,
2023 December
31, 2022 March 31,
2023 December
31, 2022 March 31,
2023 December
31, 2022 March 31,
2023 December
31, 2022
Assets:
Available-for-sale
debt securities $ 9 $ 11 $ — $ — $ 9 $ 11 $ — $ —
Investment in equity
securities 318 315 21 16 — — — —
Cross-currency swap
derivative contracts 682 653 — — 682 653 — —
Table of Contents
11

-- 14 of 42 --

Available-for-sale debt securities, which are included in other long-term assets in the accompanying Consolidated Condensed
Balance Sheets, are measured at fair value using quoted prices reported by investment brokers and dealers based on the
underlying terms of the security and comparison to similar securities traded on an active market. As of March 31, 2023 and
December 31, 2022, available-for-sale debt securities primarily included U.S. Treasury Notes and corporate debt securities.
The Company’s investments in equity securities consist of investments in publicly traded equity securities and investments in
non-marketable equity securities. The publicly traded securities are classified as Level 1 in the fair value hierarchy as they are
measured based on quotes in active markets. For the non-marketable equity securities, the Company estimates the fair value of
the investments in equity securities based on the measurement alternative and adjusts for impairments and observable price
changes with a same or similar security from the same issuer within net earnings (the “Fair Value Alternative”). The
Company’s investments in these equity securities are not classified in the fair value hierarchy due to the use of these
measurement methods. Additionally, the Company is a limited partner in partnerships that invest primarily in early-stage
companies. While the partnerships record these investments at fair value, the Company’s investments in the partnerships are
accounted for under the equity method of accounting and are not subject to fair value measurement disclosures. As of
March 31, 2023 and December 31, 2022, the Company’s equity method investments included investments in partnerships with
a carrying value of approximately $1.6 billion and $1.5 billion, respectively. Refer to Note 7 for additional information on
gains and losses on the Company’s investments including investments in the partnerships.
The cross-currency swap derivative contracts are used to partially hedge the Company’s net investments in non-U.S. operations
against adverse movements in exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and Swiss
franc. The Company also uses cross-currency swap derivative contracts to hedge the exchange rate exposure from long-term
debt issuances in a foreign currency other than the functional currency of the borrower. The cross-currency swap derivative
contracts are classified as Level 2 in the fair value hierarchy as they are measured using the income approach with the relevant
interest rates and current foreign currency exchange rates and forward curves as inputs. Refer to Note 11 for additional
information.
Fair Value of Other Financial Instruments
The carrying amounts and fair values of the Company’s other financial instruments were as follows ($ in millions):
March 31, 2023 December 31, 2022
Carrying
Amount Fair Value Carrying
Amount Fair Value
Debt obligations:
Notes payable and current portion of long-term debt $ 1,571 $ 1,551 $ 591 $ 584
Long-term debt 18,261 15,606 19,086 16,079
As of March 31, 2023 and December 31, 2022, short and long-term borrowings were categorized as Level 1. The fair value of
long-term borrowings was based on quoted market prices. The difference between the fair value and the carrying amounts of
long-term borrowings is attributable to changes in market interest rates and/or the Company’s credit ratings subsequent to the
incurrence of the borrowing. The fair values of borrowings with original maturities of one year or less, as well as cash and cash
equivalents, trade accounts receivable, net and trade accounts payable generally approximate their carrying amounts due to the
short-term maturities of these instruments.
Table of Contents
12

-- 15 of 42 --

NOTE 10. FINANCING
As of March 31, 2023, the Company was in compliance with all of its debt covenants. The components of the Company’s debt
were as follows ($ in millions):
Outstanding Amount
Description and Aggregate Principal Amount March 31, 2023 December 31,
2022
Euro-denominated commercial paper (€1.9 billion)(e) $ 2,034 $ 2,013
0.5% senior unsecured bonds due 12/08/2023 (CHF 540 million) (the “2023 CHF Bonds”)(c) 590 584
1.7% senior unsecured notes due 3/30/2024 (€900 million) (the “2024 Euronotes”)(f) 975 962
2.2% senior unsecured notes due 11/15/2024 ($700 million) (the “2024 Biopharma Notes”)(b) 699 698
3.35% senior unsecured notes due 9/15/2025 ($500 million) (the “2025 U.S. Notes”)(f) 499 499
0.2% senior unsecured notes due 3/18/2026 (€1.3 billion) (the “2026 Biopharma Euronotes”)(b) 1,351 1,333
2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”)(f) 865 854
0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”)(d) 231 234
1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”)(a) 648 639
0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma Euronotes”)(b) 1,349 1,331
1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the “2028 CHF Bonds”)(c) 232 230
2.6% senior unsecured notes due 11/15/2029 ($800 million) (the “2029 Biopharma Notes”)(b) 796 796
2.5% senior unsecured notes due 3/30/2030 (€800 million) (the “2030 Euronotes”)(f) 867 856
0.75% senior unsecured notes due 9/18/2031 (€1.8 billion) (the “2031 Biopharma Euronotes”)(b) 1,888 1,863
0.65% senior unsecured notes due 5/11/2032 (¥53.2 billion) (the “2032 Yen Notes”)(d) 399 404
1.35% senior unsecured notes due 9/18/2039 (€1.3 billion) (the “2039 Biopharma Euronotes”)(b) 1,340 1,323
3.25% senior unsecured notes due 11/15/2039 ($900 million) (the “2039 Biopharma Notes”)(b) 891 890
4.375% senior unsecured notes due 9/15/2045 ($500 million) (the “2045 U.S. Notes”)(f) 499 499
1.8% senior unsecured notes due 9/18/2049 (€750 million) (the “2049 Biopharma Euronotes”)(b) 804 794
3.4% senior unsecured notes due 11/15/2049 ($900 million) (the “2049 Biopharma Notes”)(b) 890 889
2.6% senior unsecured notes due 10/01/2050 ($1.0 billion) (the “2050 U.S. Notes”)(f) 981 981
2.8% senior unsecured notes due 12/10/2051 ($1.0 billion) (the “2051 U.S. Notes”)(f) 984 984
Other 20 21
Total debt 19,832 19,677
Less: currently payable (1,571) (591)
Long-term debt $ 18,261 $ 19,086
(a) Issued by DH Europe Finance S.A. (“Danaher International”).
(b) Issued by DH Europe Finance II S.a.r.l. (“Danaher International II”).
(c) Issued by DH Switzerland Finance S.A. (“Danaher Switzerland”).
(d) Issued by DH Japan Finance S.A. (“Danaher Japan”).
(e) Issued by Danaher Corporation or Danaher International II.
(f) Issued by Danaher Corporation.
Debt discounts, premiums and debt issuance costs totaled $114 million and $118 million as of March 31, 2023 and
December 31, 2022, respectively, and have been netted against the aggregate principal amounts of the related debt in the
components of debt table above. For additional details regarding the Company’s debt financing, refer to Note 14 of the
Company’s financial statements as of and for the year ended December 31, 2022 included in the Company’s 2022 Annual
Report.
The Company has historically satisfied short-term liquidity needs that are not met through operating cash flow and available
cash primarily through issuances of commercial paper under its U.S. dollar and euro-denominated commercial paper programs.
The Company’s $5.0 billion unsecured, multi-year revolving credit facility with a syndicate of banks that expires on August 27,
2024 (the “Five-Year Facility”), is available for direct borrowings and provides credit support for the commercial paper
programs. For a description of the Five-Year Facility, refer to the Company’s 2022 Annual Report.
As of March 31, 2023, borrowings outstanding under the Company’s euro-denominated commercial paper program had a
weighted average annual interest rate of 3.0% and a weighted average remaining maturity of approximately 48 days.
Table of Contents
13

-- 16 of 42 --

Guarantors of Debt
The Company has guaranteed long-term debt and commercial paper issued by certain of its wholly-owned finance subsidiaries:
Danaher International, Danaher International II, Danaher Switzerland and Danaher Japan. All of the outstanding and future
securities issued by each of these entities are or will be fully and unconditionally guaranteed by the Company and these
guarantees rank on parity with the Company’s unsecured and unsubordinated indebtedness.
NOTE 11. HEDGING TRANSACTIONS AND DERIVATIVE FINANCIAL INSTRUMENTS
The Company uses cross-currency swap derivative contracts to partially hedge its net investments in non-U.S. operations
against adverse movements in exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and Swiss
franc. The cross-currency swap derivative contracts are agreements to exchange fixed-rate payments in one currency for fixed-
rate payments in another currency. These contracts effectively convert U.S. dollar-denominated bonds to obligations
denominated in Danish kroner, Japanese yen, euro and Swiss franc, and partially offset the impact of changes in currency rates
on the Company’s foreign currency denominated net investments. These contracts also reduce the interest rate from the stated
interest rates on the U.S. dollar-denominated debt to the interest rates of the swaps. The changes in the spot rate of these
instruments are recorded in accumulated other comprehensive income (loss) in stockholders’ equity, partially offsetting the
foreign currency translation adjustment of the Company’s related net investment that is also recorded in accumulated other
comprehensive income (loss). The interest income or expense from these swaps are recorded in interest expense in the
accompanying Consolidated Condensed Statements of Earnings consistent with the classification of interest expense
attributable to the underlying debt. These instruments mature on dates ranging from September 2025 to November 2032.
The Company also uses cross-currency swap derivative contracts to hedge U.S. dollar-denominated long-term debt issuances in
a foreign subsidiary whose functional currency is the euro against adverse movements in exchange rates between the U.S. dollar
and the euro. These contracts effectively convert these U.S. dollar-denominated bonds to obligations denominated in euro. The
changes in the fair value of these instruments are recorded in accumulated other comprehensive income (loss), with a
reclassification from accumulated other comprehensive income (loss) to net earnings to offset the remeasurement of the hedged
debt that is also recorded in net earnings. The interest income or expense from these swaps are recorded in interest expense in
the accompanying Consolidated Condensed Statements of Earnings consistent with the classification of interest expense
attributable to the underlying debt. These instruments mature on dates ranging from November 2024 to November 2049.
The Company has also issued foreign currency denominated long-term debt as partial hedges of its net investments in foreign
operations against adverse movements in exchange rates between the U.S. dollar and the euro, Japanese yen and Swiss franc.
These foreign currency denominated long-term debt issuances are designated and qualify as nonderivative hedging instruments.
Accordingly, the foreign currency translation of these debt instruments is recorded in accumulated other comprehensive income
(loss), offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in
accumulated other comprehensive income (loss). These instruments mature on dates ranging from April 2023 to May 2032.
The Company used interest rate swap agreements to hedge the variability in cash flows due to changes in benchmark interest
rates related to a portion of the U.S. debt the Company issued to fund the acquisition of Cytiva and a portion of the 2051 U.S.
Notes. These contracts effectively fixed the interest rate for a portion of the Company’s U.S. dollar-denominated debt equal to
the notional amount of the swaps to the rate specified in the interest rate swap agreements and were settled in November 2019
and December 2021, respectively. The changes in the fair value of these instruments were recorded in accumulated other
comprehensive income (loss) prior to the issuance of the debt and are subsequently being reclassified to interest expense over
the life of the related debt.
Table of Contents
14

-- 17 of 42 --

The following table summarizes the notional values as of March 31, 2023 and April 1, 2022 and pretax impact of changes in the
fair values of instruments designated as net investment hedges and cash flow hedges in accumulated other comprehensive
income (“OCI”) for the three-month periods ended March 31, 2023 and April 1, 2022 ($ in millions):
Original
Notional Amount Notional Amount
Outstanding
Gain (Loss)
Recognized in
OCI
Amounts
Reclassified from
OCI
For the Three-Month Period Ended March 31, 2023:
Net investment hedges:
Cross-currency contracts $ 3,875 $ 3,000 $ (8) $ —
Foreign currency denominated debt 5,832 5,832 (57) —
Cash flow hedges:
Cross-currency contracts 4,000 3,300 37 43
Interest rate swaps 1,600 — — 1
Total $ 15,307 $ 12,132 $ (28) $ 44
For the Three-Month Period Ended April 1, 2022:
Net investment hedges:
Cross-currency contracts $ 3,875 $ 3,000 $ 51 $ —
Foreign currency denominated debt 3,761 3,761 124 —
Cash flow hedges:
Cross-currency contracts 4,000 4,000 125 (116)
Interest rate swaps 1,600 — — 1
Total $ 13,236 $ 10,761 $ 300 $ (115)
Gains or losses related to the net investment hedges are classified as foreign currency translation adjustments in the schedule of
changes in OCI in Note 14, as these items are attributable to the Company’s hedges of its net investment in foreign operations.
Gains or losses related to the cash flow hedges are classified as cash flow hedge adjustments in the schedule of changes in OCI
in Note 14. The amount reclassified from other comprehensive income (loss) for the cross-currency swap derivative contracts
that are cash flow hedges of the Company’s U.S. dollar-denominated debt was equal to the remeasurement amount recorded in
the three-month periods on the hedged debt.
The Company did not reclassify any other deferred gains or losses related to net investment hedges or cash flow hedges from
accumulated other comprehensive income (loss) to earnings during the three-month periods ended March 31, 2023 and April 1,
2022. In addition, the Company did not have any ineffectiveness related to net investment hedges or cash flow hedges during
the three-month periods ended March 31, 2023 and April 1, 2022, and, should they arise, any ineffective portions of the hedges
would be reclassified from accumulated other comprehensive income (loss) into earnings during the period of change. The
cash inflows and outflows associated with the Company’s derivative contracts designated as net investment hedges are
classified in all other investing activities in the accompanying Consolidated Condensed Statements of Cash Flows. The cash
inflows and outflows associated with the Company’s derivative contracts designated as cash flow hedges are classified in cash
flows from operating activities in the accompanying Consolidated Condensed Statements of Cash Flows.
The Company’s derivative instruments, as well as its nonderivative debt instruments designated and qualifying as net
investment hedges, were classified in the Company’s Consolidated Condensed Balance Sheets as follows ($ in millions):
March 31, 2023
December 31,
2022
Derivative assets:
Other long-term assets $ 682 $ 653
Nonderivative hedging instruments:
Long-term debt 5,832 5,777
Amounts related to the Company’s derivatives expected to be reclassified from accumulated other comprehensive income (loss)
to net earnings during the next 12 months, if interest rates and foreign exchange rates remain unchanged, are not significant.
Table of Contents
15

-- 18 of 42 --

NOTE 12. DEFINED BENEFIT PLANS
The following sets forth the components of the Company’s net periodic benefit costs of the noncontributory defined benefit
pension plans and other postretirement employee benefit plans ($ in millions):
Three-Month Period Ended
March 31, 2023 April 1, 2022
U.S. pension benefits:
Service cost $ — $ —
Interest cost (24) (13)
Expected return on plan assets 31 32
Amortization of actuarial loss (3) (9)
Net periodic pension benefit $ 4 $ 10
Non-U.S. pension benefits:
Service cost $ (8) $ (10)
Interest cost (12) (6)
Expected return on plan assets 9 10
Amortization of actuarial gain 2 —
Amortization of prior service credit — (10)
Net periodic pension cost $ (9) $ (16)
Other postretirement employee benefit plans:
Service cost $ — $ —
Interest cost (2) (1)
Amortization of prior service credit 1 1
Net periodic benefit cost $ (1) $ —
The service cost component of net periodic benefit costs is presented in cost of goods sold and selling, general and
administrative expenses while the other cost components are presented in other income (expense), net. The Company’s net
periodic pension cost for the three-month period ended April 1, 2022 included a settlement loss of $10 million as a result of the
transfer of a portion of its non-U.S. pension liabilities related to one defined benefit plan to a third-party.
Employer Contributions
During 2023, the Company’s cash contribution requirements for its U.S. and non-U.S. defined benefit pension plans are
forecasted to be approximately $10 million and $37 million, respectively. The ultimate amounts to be contributed depend upon,
among other things, legal requirements, underlying asset returns, the plan’s funded status, the anticipated tax deductibility of
the contribution, local practices, market conditions, interest rates and other factors.
NOTE 13. COMMITMENTS AND CONTINGENCIES
The Company reviews the adequacy of its legal reserves on a quarterly basis and establishes reserves for loss contingencies that
are both probable and reasonably estimable. For a further description of the Company’s litigation and contingencies, refer to
Note 18 of the Company’s financial statements as of and for the year ended December 31, 2022 included in the Company’s
2022 Annual Report.
The Company generally accrues estimated warranty costs at the time of sale. In general, manufactured products are warranted
against defects in material and workmanship when properly used for their intended purpose, installed correctly and
appropriately maintained. Warranty periods depend on the nature of the product and range from the date of such sale up to
twenty years. The amount of the accrued warranty liability is determined based on historical information such as past
experience, product failure rates or number of units repaired, estimated cost of material and labor and in certain instances
estimated property damage. As of March 31, 2023 and December 31, 2022, the Company had accrued warranty liabilities of
$96 million and $95 million, respectively.
Table of Contents
16

-- 19 of 42 --

NOTE 14. STOCKHOLDERS' EQUITY AND STOCK-BASED COMPENSATION
Stockholders’ Equity
On July 16, 2013, the Company’s Board of Directors approved a repurchase program (the “Repurchase Program”) authorizing
the repurchase of up to 20 million shares of the Company’s common stock from time to time on the open market or in privately
negotiated transactions. As of March 31, 2023, approximately 20 million shares remained available for repurchase pursuant to
the Repurchase Program.
The following table summarizes the Company’s share activity (shares in millions):
Three-Month Period Ended
March 31, 2023 April 1, 2022
Preferred stock - shares issued:
Balance, beginning and end of period 1.7 3.4
Common stock - shares issued:
Balance, beginning of period 869.3 855.7
Common stock-based compensation awards 1.1 1.3
Balance, end of period 870.4 857.0
Unless converted earlier in accordance with the terms of the certificate of designations, each share of MCPS Series B
mandatorily converted on April 17, 2023 (the Mandatory Conversion Date) into 5.0175 shares of Company common stock. In
aggregate, the MCPS Series B converted into 8.6 million shares of Company common stock and the Company issued cash in
lieu of fractional shares of common stock in the conversion. The number of shares of the Company’s common stock issued
upon conversion was determined based on the average volume-weighted average price per share of the Company’s common
stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately
before the Mandatory Conversion Date.
Subject to certain exceptions, at any time prior to the Mandatory Conversion Date, holders could elect to convert the MCPS
Series B shares into common stock based on the Minimum Conversion Rate (subject to further anti-dilution adjustments). In
the three-months ended March 31, 2023, holders converted 55 shares of MCPS Series B into 275 shares of Danaher common
stock.
Prior to their conversion, holders of MCPS Series B were entitled to receive, cumulative dividends at the Annual Cumulative
Dividend Rate of 5.00% of the Liquidation Preference of $1,000 per share, payable in cash or, subject to certain limitations, by
delivery of shares of the Company’s common stock or any combination of cash and shares of the Company’s common stock, at
the Company’s election. In 2023, cash dividends on the MCPS Series B shares were paid on January 15, 2023 and April 17,
2023 to the holders of record of the MCPS Series B shares as they appeared on the Company’s stock register at the close of
business on the immediately preceding December 31, 2022 and March 31, 2023, respectively. The impact of the MCPS Series
B calculated under the if-converted method was anti-dilutive for the periods in 2023 prior to conversion.
On April 15, 2022, all outstanding shares of the Company’s 4.75% MCPS Series A converted to common shares at a rate of
6.6632 common shares per share of preferred stock into an aggregate of 11.0 million shares of the Company’s common stock,
pursuant to the terms of the Certificate of Designation governing the Series A Preferred Stock. For additional information on
the conversion of MCPS Series A, refer to Note 19 in the Company’s 2022 Annual Report.
Stock-Based Compensation
For a full description of the Company’s stock-based compensation programs, refer to Note 19 of the Company’s financial
statements as of and for the year ended December 31, 2022 included in the Company’s 2022 Annual Report. As of March 31,
2023, approximately 41 million shares of the Company’s common stock were reserved for issuance under the 2007 Omnibus
Incentive Plan.
Table of Contents
17

-- 20 of 42 --

The following summarizes the components of the Company’s stock-based compensation expense ($ in millions):
Three-Month Period Ended
March 31, 2023 April 1, 2022
RSUs/PSUs:
Pretax compensation expense $ 46 $ 46
Income tax benefit (9) (9)
RSU/PSU expense, net of income taxes 37 37
Stock options:
Pretax compensation expense 33 34
Income tax benefit (7) (7)
Stock option expense, net of income taxes 26 27
Total stock-based compensation:
Pretax compensation expense 79 80
Income tax benefit (16) (16)
Total stock-based compensation expense, net of income taxes $ 63 $ 64
Stock-based compensation has been recognized as a component of selling, general and administrative expenses in the
accompanying Consolidated Condensed Statements of Earnings. As of March 31, 2023, $333 million of total unrecognized
compensation cost related to RSUs/PSUs is expected to be recognized over a weighted average period of approximately two
years. As of March 31, 2023, $353 million of total unrecognized compensation cost related to stock options is expected to be
recognized over a weighted average period of approximately two years. Future compensation amounts will be adjusted for any
changes in estimated forfeitures.
Table of Contents
18

-- 21 of 42 --

Accumulated Other Comprehensive Income
Accumulated other comprehensive income (loss) refers to certain gains and losses that under U.S. GAAP are included in
comprehensive income (loss) but are excluded from net earnings as these amounts are initially recorded as an adjustment to
stockholders’ equity. Foreign currency translation adjustments generally relate to indefinite investments in non-U.S.
subsidiaries, as well as the impact from the Company’s hedges of its net investment in foreign operations, including the
Company’s cross-currency swap derivatives, net of any income tax impacts.
The changes in accumulated other comprehensive income (loss) by component are summarized below ($ in millions).
Foreign
Currency
Translation
Adjustments
Pension and
Postretirement
Plan Benefit
Adjustments
Cash Flow
Hedge
Adjustments
Accumulated
Comprehensive
Income (Loss)
For the Three-Month Period Ended March 31, 2023:
Balance, December 31, 2022 $ (2,644) $ (341) $ 113 $ (2,872)
Other comprehensive income (loss) before reclassifications:
Increase (decrease) 23 — 37 60
Income tax impact 2 — — 2
Other comprehensive income (loss) before reclassifications,
net of income taxes 25 — 37 62
Reclassification adjustments:
Increase (decrease) — — (a) 44 (b) 44
Income tax impact — — — —
Reclassification adjustments, net of income taxes — — 44 44
Net other comprehensive income (loss), net of income
taxes 25 — 81 106
Balance, March 31, 2023 $ (2,619) $ (341) $ 194 $ (2,766)
For the Three-Month Period Ended April 1, 2022:
Balance, December 31, 2021 $ (539) $ (550) $ 62 $ (1,027)
Other comprehensive income (loss) before reclassifications:
Increase (decrease) (331) — 125 (206)
Income tax impact (12) — (30) (42)
Other comprehensive income (loss) before reclassifications,
net of income taxes (343) — 95 (248)
Reclassification adjustments:
Increase (decrease) — 18 (a) (115) (b) (97)
Income tax impact — (4) — (4)
Reclassification adjustments, net of income taxes — 14 (115) (101)
Net other comprehensive income (loss), net of income
taxes (343) 14 (20) (349)
Balance, April 1, 2022 $ (882) $ (536) $ 42 $ (1,376)
(a) This accumulated other comprehensive income (loss) component is included in the computation of net periodic benefit cost (refer to Notes
7 and 12 for additional details).
(b) Reflects reclassification to earnings related to cash flow hedges of certain long-term debt (refer to Note 11 for additional details).
Table of Contents
19

-- 22 of 42 --

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is designed to provide
material information relevant to an assessment of Danaher Corporation’s (“Danaher,” the “Company,” “we,” “us” or “our”)
financial condition and results of operations, including an evaluation of the amounts and certainty of cash flows from operations
and from outside sources. The MD&A is designed to focus specifically on material events and uncertainties known to
management that are reasonably likely to cause reported financial information not to be necessarily indicative of future
operating results or of future financial condition. This includes descriptions and amounts of matters that have had a material
impact on reported operations, as well as matters that are reasonably likely based on management’s assessment to have a
material impact on future operations. The Company’s MD&A is divided into five sections:
• Information Relating to Forward-Looking Statements
• Overview
• Results of Operations
• Liquidity and Capital Resources
• Critical Accounting Estimates
You should read this discussion along with the Company’s MD&A and audited financial statements and Notes thereto as of and
for the year ended December 31, 2022, included in the Company’s 2022 Annual Report and the Company’s Consolidated
Condensed Financial Statements and related Notes as of and for the three-month period ended March 31, 2023 included in this
Quarterly Report on Form 10-Q (“Report”).
INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS
Certain statements included or incorporated by reference in this Report, in other documents we file with or furnish to the
Securities and Exchange Commission, in our press releases, webcasts, conference calls, materials delivered to shareholders and
other communications, are “forward-looking statements” within the meaning of the U.S. federal securities laws. All statements
other than historical factual information are forward-looking statements, including without limitation statements regarding:
projections of revenue, expenses, profit, profit margins, pricing, tax rates, tax provisions, cash flows, pension and benefit
obligations and funding requirements, our liquidity position or other projected financial measures; management’s plans and
strategies for future operations, including statements relating to anticipated operating performance, cost reductions,
restructuring activities, new product and service developments, competitive strengths or market position, acquisitions and the
integration thereof, divestitures, spin-offs, split-offs, initial public offerings, other securities offerings, or other distributions,
strategic opportunities, stock repurchases, dividends and executive compensation; growth, declines and other trends in markets
we sell into; new or modified laws, regulations and accounting pronouncements; future regulatory approvals and the timing and
conditionality thereof; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; future
foreign currency exchange rates and fluctuations in those rates; the potential or anticipated direct or indirect impact of
COVID-19 on our business, results of operations and/or financial condition; general economic and capital markets conditions;
the anticipated timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that
address events or developments that Danaher intends or believes will or may occur in the future. Terminology such as
“believe,” “anticipate,” “should,” “could,” “intend,” “will,” “plan,” “expect,” “estimate,” “project,” “target,” “may,” “possible,”
“potential,” “forecast” and “positioned” and similar references to future periods are intended to identify forward-looking
statements, although not all forward-looking statements are accompanied by such words.
Forward-looking statements are based on assumptions and assessments made by our management in light of their experience
and perceptions of historical trends, current conditions, expected future developments and other factors. Forward-looking
statements are not guarantees of future performance and actual results may differ materially from the results, developments and
business decisions contemplated by our forward-looking statements. Accordingly, you should not place undue reliance on any
such forward-looking statements. Important factors that in some cases have affected us in the past and that in the future could
cause actual results to differ materially from those envisaged in the forward-looking statements include the following:
Business and Strategic Risks
• The COVID-19 pandemic has adversely impacted and could in the future continue to adversely impact elements of our
business and financial statements. Other conditions in the global economy, the particular markets we serve and the
financial markets can also adversely affect our business and financial statements.
Table of Contents
20

-- 23 of 42 --

• We face intense competition and if we are unable to compete effectively, we may experience decreased demand and
decreased market share. Even if we compete effectively, we may be required to reduce the prices we charge.
• Our growth depends on the timely development and commercialization, and customer acceptance, of new and
enhanced products and services based on technological innovation. Our growth can also suffer if the markets into
which we sell our products and services decline, do not grow as anticipated or experience cyclicality.
• The healthcare industry and related industries that we serve are undergoing significant changes in an effort to reduce
(and increase the predictability of) costs, which can adversely affect our business and financial statements.
• Non-U.S. economic, political, legal, compliance, social and business factors (such as the military conflict between
Russia and Ukraine) can negatively affect our business and financial statements.
• Collaborative partners and other third-parties we rely on for development, supply and/or marketing of certain products,
potential products and technologies could fail to perform sufficiently.
Acquisitions, Divestitures and Investment Risks
• Any inability to consummate acquisitions at our historical rate and appropriate prices, and to make appropriate
investments that support our long-term strategy, could negatively impact our business.
• Our acquisition of businesses, investments, joint ventures and other strategic relationships could also negatively impact
our business and financial statements and our indemnification rights may not fully protect us from liabilities related
thereto.
• We intend to separate our Environmental & Applied Solutions (“EAS”) segment to create a publicly-traded company,
to be known as Veralto Corporation (“Veralto”), in the fourth quarter of 2023 (the “EAS Separation”). The proposed
transaction may not be completed on the currently contemplated timeline or at all and may not achieve the intended
benefits.
• Divestitures or other dispositions (including the anticipated EAS Separation) could negatively impact our business, and
contingent liabilities from EAS or from businesses that we or our predecessors have previously disposed could
adversely affect our business and financial statements. For example, we could incur significant liability if the EAS
Separation or any of the split-off or spin-off transactions we have previously consummated are determined to be a
taxable transaction or otherwise pursuant to our indemnification obligations with respect to such transactions.
Operational Risks
• Significant disruptions in, or breaches in security of, our information technology (“IT”) systems or data; data privacy
violations; other losses or disruptions to facilities, supply chains, distribution systems or IT systems due to catastrophe;
and labor disputes can all adversely affect our business and financial statements.
• Defects and unanticipated use or inadequate disclosure with respect to our products or services, or allegations thereof,
can adversely affect our business and financial statements.
• Our financial results are subject to fluctuations in the cost and availability of the supplies (including commodities) we
use in, and the labor we need for, our operations. Over the past year, we have at times experienced to varying degrees
supply chain disruptions including in some cases shortages of supply, cost inflation and shipping delays, labor
availability constraints and labor cost increases.
• Climate change, legal or regulatory measures to address climate change and any inability to address stakeholder
expectations with respect to climate change, may negatively affect us.
• Our success depends on our ability to recruit, retain and motivate talented employees representing diverse
backgrounds, experiences and skill sets.
• Our restructuring actions can have long-term adverse effects on our business and financial statements.
Intellectual Property Risks
• Any inability to adequately protect or avoid third-party infringement of our intellectual property, and third-party
claims we are infringing intellectual property rights, can adversely affect our business and financial statements.
Table of Contents
21

-- 24 of 42 --

• The U.S. government has certain rights with respect to incremental production capacity attributable to, and/or the
intellectual property we have developed using, government financing. In addition, in times of national emergency the
U.S. government has authority to control our allocation of manufacturing capacity.
Financial and Tax Risks
• Our outstanding debt has increased significantly as a result of acquisitions, and we may incur additional debt. Such
indebtedness may limit our operations and use of cash flow and negatively impact our credit ratings; and failure to
comply with our indebtedness-related covenants could adversely affect our business and financial statements.
• Our business and financial statements can be adversely affected by foreign currency exchange rates, changes in our tax
rates (including as a result of changes in tax laws) or income tax liabilities/assessments, the outcome of tax audits,
financial market risks related to our defined benefit pension plans, health care costs and recognition of impairment
charges for our goodwill or other intangible assets.
Legal, Regulatory, Compliance and Reputational Risks
• Significant developments or changes in national laws or policies to protect or promote domestic interests and/or
address foreign competition can have an adverse effect on our business and financial statements.
• Our businesses are subject to extensive regulation (including those applicable to the healthcare industry). Failure to
comply with those regulations (including by our employees, agents or business partners) or significant developments
or changes in laws or policies can adversely affect our business and financial statements.
• With respect to the regulated medical devices we offer, product introductions or modifications may require regulatory
clearance or authorizations and we could be required to recall or cease marketing such products; off-label marketing
could result in penalties; and clinical trials may have results that are unexpected or are perceived unfavorably by the
market, all of which could adversely affect our business and financial statements.
• We are subject to or otherwise responsible for a variety of litigation and other legal and regulatory proceedings in the
course of our business that can adversely affect our business and financial statements.
• Our operations, products and services also expose us to the risk of environmental, health and safety liabilities, costs
and violations that could adversely affect our business and financial statements.
• Our By-law exclusive forum provisions could limit our stockholders’ ability to choose their preferred judicial forum
for disputes.
See “Part I—Item 1A. Risk Factors” of the Company’s 2022 Annual Report for further discussion regarding reasons that actual
results may differ materially from the results, developments and business decisions contemplated by our forward-looking
statements. Forward-looking statements speak only as of the date of the report, document, press release, webcast, call,
materials or other communication in which they are made. Except to the extent required by applicable law, we do not assume
any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and
developments or otherwise.
OVERVIEW
General
As a result of the Company’s geographic and industry diversity, the Company faces a variety of opportunities and challenges,
including rapid technological development in most of the Company’s served markets, the expansion and evolution of
opportunities in high-growth markets, trends and costs associated with a global labor force, consolidation of the Company’s
competitors and increasing regulation. The Company operates in a highly competitive business environment in most markets,
and the Company’s long-term growth and profitability will depend in particular on its ability to expand its business in high-
growth geographies and high-growth market segments, identify, consummate and integrate appropriate acquisitions and identify
and consummate appropriate investments and strategic partnerships, develop innovative and differentiated new products and
services with higher gross profit margins, expand and improve the effectiveness of the Company’s sales force, continue to
reduce costs and improve operating efficiency and quality and effectively address the demands of an increasingly regulated
global environment. The Company is making significant investments, organically and through acquisitions and investments, to
address the rapid pace of technological change in its served markets and to globalize its manufacturing, research and
development and customer-facing resources (particularly in high-growth markets) to be responsive to the Company’s customers
throughout the world and improve the efficiency of the Company’s operations.
Table of Contents
22

-- 25 of 42 --

Business Performance and Outlook
During the first quarter of 2023, the Company’s overall revenues decreased 7.0% compared to the comparable period of 2022.
Core sales decreased 4.0% in the first quarter of 2023 compared to the comparable prior year period due primarily to the decline
of demand for COVID-19-related products, partially offset by increases in demand for other products. The impact of currency
translation decreased reported sales 3.0% in the first quarter of 2023 compared to the comparable prior year period. For the
definition of “core sales” refer to “—Results of Operations” below.
Geographically, the Company saw a decrease in core sales in the developed markets, partially offset by an increase in core sales
in the high-growth markets during the first quarter of 2023 compared to the first quarter of 2022. Developed markets core sales
decreased at a mid-single digit rate, driven primarily by declines in core sales in North America primarily driven by reduced
demand for products and services related to vaccine and therapeutics production and diagnostic testing associated with
COVID-19. High-growth markets core sales increased at a low-single digit rate as declines in China were offset by growth in
other regions. High-growth markets represented approximately 29% of the Company’s total sales in the first quarter of 2023.
For additional information regarding the Company’s sales by geographical region during the three-month periods ended
March 31, 2023 and April 1, 2022, refer to Note 4 to the accompanying Consolidated Condensed Financial Statements.
The Company’s net earnings for the three-month period ended March 31, 2023 totaled approximately $1.5 billion, compared to
approximately $1.7 billion for the three-month period ended April 1, 2022. Net earnings attributable to common stockholders
for the three-month period ended March 31, 2023 totaled approximately $1.4 billion or $1.94 per diluted common share,
compared to approximately $1.7 billion or $2.31 per diluted common share for the three-month period ended April 1, 2022.
Decreased core sales and the adverse impact of foreign currency exchange rates in the 2023 period drove the year-over-year
decrease in net earnings and diluted net earnings per common share for the three-month period ended March 31, 2023.
In an effort to moderate inflationary pressure, the U.S. Federal Reserve and other central banks around the world have raised
interest rates, which has tightened the global credit environment. While the Company’s interest costs and liquidity have not
been significantly impacted by this credit tightening due to the significant cash flow generated from the Company’s operations
and the predominantly fixed-interest rates of the Company’s outstanding borrowings, the credit tightening has adversely
impacted demand at certain of the Company’s customers, including emerging biotechnology companies.
The COVID-19 Pandemic
The Company continues to actively monitor the COVID-19 pandemic. While conditions related to the pandemic generally have
improved in 2023 compared to 2022, conditions vary by geography. During the fourth quarter of 2022, China eased many
COVID-19 related restrictions and began experiencing increased COVID-19 related cases. This resulted in lower patient
volumes for elective procedures and wellness visits as hospitals prioritized treating COVID-19 related cases, which in turn
resulted in reduced demand for many of the Company’s non-COVID-19 products and services in China. These higher
COVID-19 related cases in China continued into the early part of the first quarter of 2023.
The Company has also deployed our capabilities, expertise and scale to address the critical health needs related to COVID-19,
including making available diagnostic tests for the rapid detection of COVID-19 and support for production of vaccines and
therapies for COVID-19. Demand for the Company’s products that support COVID-19 related vaccines and therapeutics
(including related to research and development that seeks to prevent or mitigate similar, future pandemics) decreased in the first
quarter of 2023 versus the comparable period of 2022. The Company expects overall demand for these products to continue to
decrease in 2023 compared to 2022 as the pandemic continues to subside in most geographies and evolve towards endemic
status. Additionally, demand for the Company’s products that support COVID-19 testing is expected to continue to fluctuate,
corresponding to fluctuations in COVID-19 cases in particular geographies. In response to COVID-19 evolving to an endemic
status, the Company expects to continue to review and adjust its cost structure, particularly within the Diagnostics and
Biotechnology segments.
On April 10, 2023, the U.S. announced that the public health emergency related to COVID-19 ended. The Company does not
anticipate significant impact from the expiration of the public health emergency.
For additional information on the risks of COVID-19 to the Company’s operations, refer to the “Item 1A. Risk Factors” section
of the Company’s 2022 Annual Report.
Proposed Separation of the Environmental & Applied Solutions Business
For a description of Danaher’s plan to separate its Environmental & Applied Solutions business into a publicly traded company,
see “Results of Operations—Environmental & Applied Solutions.”
Table of Contents
23

-- 26 of 42 --

Currency Exchange Rates
On a year-over-year basis, currency exchange rates negatively impacted reported sales by approximately 3.0% for the three-
month period ended March 31, 2023 compared to the comparable period of 2022, primarily due to the strengthening of the U.S.
dollar against the euro and most other major currencies in 2023. If the currency exchange rates in effect as of March 31, 2023
were to prevail throughout the remainder of 2023, currency exchange rates would decrease the Company’s estimated first half
2023 sales by approximately 1.5% and full year 2023 sales would be essentially flat relative to 2022. Further strengthening of
the U.S. dollar against other major currencies compared to the exchange rates in effect as of March 31, 2023 would adversely
impact the Company’s sales on an overall basis, and any weakening of the U.S. dollar against other major currencies compared
to the exchange rates in effect as of March 31, 2023 would positively impact the Company’s sales and results of operations for
the remainder of the year.
RESULTS OF OPERATIONS
Non-GAAP Measures
In this report, references to the non-GAAP measures of core sales (also referred to as core revenues or sales/revenues from
existing businesses) refer to sales calculated according to U.S. GAAP, but excluding:
• sales from acquired businesses (as defined below, as applicable); and
• the impact of currency translation.
References to sales or operating profit attributable to acquisitions or acquired businesses refer to sales or operating profit, as
applicable, from acquired businesses recorded prior to the first anniversary of the acquisition less any sales and operating profit,
during the applicable period, attributable to divested product lines not considered discontinued operations. The portion of
revenue attributable to currency translation is calculated as the difference between:
• the period-to-period change in revenue (excluding sales from acquired businesses (as defined above, as applicable));
and
• the period-to-period change in revenue (excluding sales from acquired businesses (as defined above, as applicable))
after applying current period foreign exchange rates to the prior year period.
Core sales growth should be considered in addition to, and not as a replacement for or superior to, sales, and may not be
comparable to similarly titled measures reported by other companies. Management believes that reporting this non-GAAP
financial measure provides useful information to investors by helping identify underlying growth trends in Danaher’s business
and facilitating comparisons of Danaher’s revenue performance with its performance in prior and future periods and to
Danaher’s peers. Management also uses this non-GAAP financial measure to measure the Company’s operating and financial
performance and uses core sales growth as one of the performance measures in the Company’s executive short-term cash
incentive compensation program. The Company excludes the effect of currency translation from this measure because currency
translation is not under management’s control, is subject to volatility and can obscure underlying business trends, and excludes
the effect of acquisitions and divestiture-related items because the nature, size, timing and number of acquisitions and
divestitures can vary dramatically from period-to-period and between the Company and its peers and can also obscure
underlying business trends and make comparisons of long-term performance difficult.
Throughout this discussion, references to sales growth or decline refer to the impact of both price and unit sales and references
to productivity improvements generally refer to improved cost-efficiencies resulting from the ongoing application of the
Danaher Business System.
Sales (Decline) Growth and Core Sales (Decline) Growth
% Change Three-
Month Period Ended
March 31, 2023 vs.
Comparable 2022
Period
Total sales (decline) growth (GAAP) (7.0) %
Impact of:
Currency exchange rates 3.0 %
Core sales (decline) growth (non-GAAP) (4.0) %
Table of Contents
24

-- 27 of 42 --

2023 Sales Compared to 2022
Total sales decreased 7.0% during the three-month period ended March 31, 2023 compared to the three-month period ended
April 1, 2022, primarily as a result of the decrease in core sales due to the factors discussed below by segment. The impact of
currency translation decreased reported sales 3.0% on a year-over-year basis during the three-month period ended March 31,
2023, primarily due to the unfavorable impact of the strengthening of the U.S. dollar against the euro and most other major
currencies in 2023. Price increases contributed 3.0% to sales growth on a year-over-year basis during the three-month period
ended March 31, 2023, and are reflected as a component of core sales decline above.
Operating Profit Performance
Operating profit margins decreased 330 basis points from 28.3% during the three-month period ended April 1, 2022 to 25.0%
for the three-month period ended March 31, 2023.
First quarter 2023 vs. first quarter 2022 operating profit margin comparisons were favorably impacted by:
• First quarter 2022 impairments of accounts receivable and inventory as well as accruals for contractual obligations in
Russia - 55 basis points
First quarter 2023 vs. first quarter 2022 operating profit margin comparisons were unfavorably impacted by:
• Lower first quarter 2023 core sales, the impact of product mix and incremental year-over-year costs associated with
sales and marketing growth initiatives, net of incremental year-over-year cost savings associated with material,
transportation and labor costs and restructuring and continuing productivity improvement initiatives - 330 basis points
• First quarter 2023 costs incurred related to preparation for the anticipated separation of the Company's Environmental
& Applied Solutions business - 40 basis points
• The incremental dilutive effect in 2023 of acquired businesses - 15 basis points
Business Segments
Sales by business segment for each of the periods indicated were as follows ($ in millions):
Three-Month Period Ended
March 31, 2023 April 1, 2022
Biotechnology $ 1,864 $ 2,216
Life Sciences 1,709 1,666
Diagnostics 2,376 2,644
Environmental & Applied Solutions 1,218 1,162
Total $ 7,167 $ 7,688
For information regarding the Company’s sales by geographical region, refer to Note 4 to the accompanying Consolidated
Condensed Financial Statements.
BIOTECHNOLOGY
The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of tools,
consumables and services that are primarily used by customers to advance and accelerate the research, development,
manufacture and delivery of biological medicines. The biotherapeutics that the Company’s solutions support range from
replacement therapies such as insulin, vaccines, recombinant proteins and other biologic drugs, to novel cell, gene, mRNA and
other nucleic acid therapies.
Table of Contents
25

-- 28 of 42 --

Biotechnology Selected Financial Data
Three-Month Period Ended
($ in millions) March 31, 2023 April 1, 2022
Sales $ 1,864 $ 2,216
Operating profit 596 800
Depreciation 40 44
Amortization of intangible assets 217 214
Operating profit as a % of sales 32.0 % 36.1 %
Depreciation as a % of sales 2.1 % 2.0 %
Amortization as a % of sales 11.6 % 9.7 %
Sales (Decline) Growth and Core Sales (Decline) Growth
% Change Three-
Month Period Ended
March 31, 2023 vs.
Comparable 2022
Period
Total sales (decline) growth (GAAP) (16.0) %
Impact of:
Currency exchange rates 3.0 %
Core sales (decline) growth (non-GAAP) (13.0) %
Price increases in the segment contributed 3.5% to sales growth on a year-over-year basis during the three-month period ended
March 31, 2023 and are reflected as a component of core sales decline above.
Total segment sales decreased 16.0% during the three-month period, led by decreased core sales resulting from the factors
discussed below and by the impact of changes in currency exchange rates. Core sales in the bioprocessing business decreased
during the three-month period across most major geographies primarily due to declining demand for COVID-19 related
therapeutics and vaccines and as customers continued the repurposing of inventory initially purchased for COVID-19
therapeutics and vaccines. This decline was offset in part by increased core sales for non-COVID-19 related products. The
Company expects the impact of reduced COVID-19 demand and reduction of inventory levels to continue into the second half
of 2023. Additionally, the tightening credit environment contributed to a reduction in demand from emerging biotechnology
companies during the quarter. Core sales in the discovery and medical business decreased during the three-month period due to
decreased sales in lab filtration, medical and diagnostics and genomics product lines, partially offset by growth in protein
research products. Geographically, core sales decreased in North America.
Operating Profit Performance
Operating profit margins decreased 410 basis points during the three-month period ended March 31, 2023 as compared to the
comparable period of 2022.
First quarter 2023 vs. first quarter 2022 operating profit margin comparisons were favorably impacted by:
• First quarter 2022 impairments of accounts receivable and inventory in Russia - 60 basis points
First quarter 2023 vs. first quarter 2022 operating profit margin comparisons were unfavorably impacted by:
• Lower first quarter 2023 core sales, the impact of product mix, a year-over-year increase in sales and marketing
growth initiatives and higher amortization expense, net of lower incremental year-over-year costs associated with
material, transportation and labor, restructuring and continuing productivity improvement initiatives - 455 basis points
• The incremental dilutive effect in 2023 of acquired businesses - 15 basis points
Amortization of intangible assets as a percentage of sales increased during the three-month period ended March 31, 2023 as
compared with 2022 primarily as a result of the decrease in sales and increased year-over year amortization from the change of
a trade name from indefinite-lived to definite-lived.
Table of Contents
26

-- 29 of 42 --

LIFE SCIENCES
The Life Sciences segment offers a broad range of instruments and consumables that are primarily used by customers to study
the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand
the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies.
Additionally, the segment provides products and consumables used to filter and remove contaminants from a variety of liquids
and gases in many end-market applications.
Life Sciences Selected Financial Data
Three-Month Period Ended
($ in millions) March 31, 2023 April 1, 2022
Sales $ 1,709 $ 1,666
Operating profit 321 318
Depreciation 29 28
Amortization of intangible assets 105 107
Operating profit as a % of sales 18.8 % 19.1 %
Depreciation as a % of sales 1.7 % 1.7 %
Amortization as a % of sales 6.1 % 6.4 %
Sales Growth and Core Sales Growth
% Change Three-
Month Period Ended
March 31, 2023 vs.
Comparable 2022
Period
Total sales growth (GAAP) 2.5 %
Impact of:
Acquisitions/divestitures (1.0) %
Currency exchange rates 3.5 %
Core sales growth (non-GAAP) 5.0 %
Price increases in the segment contributed 4.5% to sales growth on a year-over-year basis during the three-month period ended
March 31, 2023 and are reflected as a component of core sales growth.
Total segment sales increased 2.5% during the three-month period, led by increased core sales resulting from the factors
discussed below, and acquisitions, partially offset by the impact of changes in currency exchange rates. Total segment core
sales were impacted by the decline in COVID-19 related sales. Core sales for the Company’s flow cytometry, genomics, lab
automation, centrifugation, particle counting and characterization business increased in the three-month period, primarily due to
increased demand in the flow cytometry, particle counting and centrifugation product lines, partially offset by lower demand for
automation and genomic products related to COVID-19. Geographically, core sales increased in Western Europe and China,
partially offset by lower sales in North America. Core sales in the mass spectrometry business increased during the three-
month period led by life science research, clinical and service end-markets. Geographically, the increase in core sales was
driven by increased demand for consumables in China and Western Europe, partially offset by lower sales in North America.
Core sales for the genomic consumables businesses decreased due to reduced demand for COVID-19 related products, partially
offset by increased demand for non-COVID-19 related products. Geographically, the decrease in core sales was driven by
North America, partially offset by increased demand in Western Europe. Core sales for the industrial filtration business
increased due to strong demand for these products across all major geographies and all major end-markets.
Operating Profit Performance
Operating profit margins decreased 30 basis points during the three-month period ended March 31, 2023 as compared to the
comparable period of 2022.
First quarter 2023 vs. first quarter 2022 operating profit margin comparisons were favorably impacted by:
• First quarter 2022 impairments of accounts receivable and inventory as well as accruals for contractual obligations in
Russia - 145 basis points
Table of Contents
27

-- 30 of 42 --

First quarter 2023 vs. first quarter 2022 operating profit margin comparisons were unfavorably impacted by:
• The impact of product mix and incremental year-over-year costs associated with material, transportation and labor and
sales and marketing growth initiatives, net of higher first quarter 2023 core sales and the incremental year-over-year
cost savings associated with restructuring and continuing productivity improvement initiatives - 130 basis points
• The incremental dilutive effect in 2023 of acquired businesses - 45 basis points
Amortization of intangible assets decreased as a percentage of sales during the three-month period ended March 31, 2023,
primarily as a result of the increase in sales.
DIAGNOSTICS
The Diagnostics segment offers clinical instruments, reagents, consumables, software and services that hospitals, physicians’
offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
Diagnostics Selected Financial Data
Three-Month Period Ended
($ in millions) March 31, 2023 April 1, 2022
Sales $ 2,376 $ 2,644
Operating profit 677 886
Depreciation 93 94
Amortization of intangible assets 50 51
Operating profit as a % of sales 28.5 % 33.5 %
Depreciation as a % of sales 3.9 % 3.6 %
Amortization as a % of sales 2.1 % 1.9 %
Sales (Decline) Growth and Core Sales (Decline) Growth
% Change Three-
Month Period Ended
March 31, 2023 vs.
Comparable 2022
Period
Total sales (decline) growth (GAAP) (10.0) %
Impact of:
Currency exchange rates 2.5 %
Core sales (decline) growth (non-GAAP) (7.5) %
Price increases in the segment contributed 1.0% to sales growth on a year-over-year basis during the three-month period ended
March 31, 2023 and are reflected as a component of core sales decline.
Total segment sales decreased 10.0% during the three-month period, primarily as a result of decreased core sales resulting from
the factors discussed below, particularly lower year-over-year core sales of molecular diagnostics tests for COVID-19, which
contributed significantly to the decline in overall segment core sales, and the impact of changes in currency exchange rates.
During the three-month period, core sales in the molecular diagnostics business decreased on a year-over-year basis across most
major geographic regions as the business experienced declines in sales of diagnostic test solutions for COVID-19, partially
offset by increased sales of non-respiratory disease tests. Core sales in the segment’s clinical lab business increased on a year-
over-year basis, led by increased sales in the immunoassay product line. Geographically, the increase in core sales was driven
by North America and China. Core sales in the acute care diagnostic business increased year-over-year in the three-month
period primarily due to increased demand for its blood gas measurement product line. Geographically, demand increased
across all major geographies, led by China. Core sales in the pathology business increased year-over-year driven by advanced
staining and core histology and consumables in the three-month period, led geographically by Western Europe, North America
and China.
Table of Contents
28

-- 31 of 42 --

Operating Profit Performance
Operating profit margins decreased 500 basis points during the three-month period ended March 31, 2023 as compared to the
comparable period of 2022.
First quarter 2023 vs. first quarter 2022 operating profit margin comparisons were favorably impacted by:
• First quarter 2022 impairments of accounts receivable and accruals for contractual obligations in Russia - 10 basis
points
First quarter 2023 vs. first quarter 2022 operating profit margin comparisons were unfavorably impacted by:
• Lower first quarter 2023 core sales, the impact of product mix and the incremental year-over-year costs associated
with sales and marketing growth initiatives, net of incremental year-over-year cost savings associated with
restructuring and continuing productivity improvement initiatives - 510 basis points
ENVIRONMENTAL & APPLIED SOLUTIONS
The Environmental & Applied Solutions segment is a provider of essential technology solutions that safeguard many of the
world's most vital resources and support customers to address large global challenges including environmental resource
sustainability, water scarcity, management of severe weather events, food and pharmaceutical security and the impact of an
aging workforce. The Company’s water quality business provides proprietary precision instrumentation and advanced water
treatment technologies to help measure, analyze and treat the world’s water in residential, commercial, municipal, industrial,
research and natural resource applications. In addition to instrumentation, the water quality businesses also provide chemical
reagents, services and digital solutions. The Company’s product identification business provides marking and coding, and
packaging and color instrumentation and related consumables for brand owners and consumer packaged goods companies that
enable speed to market as well as traceability and quality control of their products. The product identification business’s
solutions help customers across consumer, pharmaceutical and industrial sectors to bring products to market, mark packaging in
compliance with industry and regulatory standards and convey the safety of products to their customers.
Environmental & Applied Solutions Selected Financial Data
Three-Month Period Ended
($ in millions) March 31, 2023 April 1, 2022
Sales $ 1,218 $ 1,162
Operating profit 299 236
Depreciation 10 11
Amortization of intangible assets 12 14
Operating profit as a % of sales 24.5 % 20.3 %
Depreciation as a % of sales 0.8 % 0.9 %
Amortization as a % of sales 1.0 % 1.2 %
Sales Growth and Core Sales Growth
% Change Three-
Month Period Ended
March 31, 2023 vs.
Comparable 2022
Period
Total sales growth (GAAP) 5.0 %
Impact of:
Acquisitions/divestitures (0.5) %
Currency exchange rates 2.0 %
Core sales growth (non-GAAP) 6.5 %
Price increases in the segment contributed 5.0% to sales growth on a year-over-year basis during the three-month period ended
March 31, 2023 and are reflected as a component of core sales growth.
Total segment sales increased 5.0% during the three-month period primarily as a result of core sales growth driven by the
factors discussed below and acquisitions, partially offset by the impact of changes in currency exchange rates.
Table of Contents
29

-- 32 of 42 --

Core sales in the segment’s water quality businesses increased at a low-double digit rate during the three-month period ended
March 31, 2023, compared to the comparable period of 2022. Year-over-year core sales in the analytical instrumentation
product line increased in the three-month period driven by increased core sales in the municipal and industrial end-markets.
Geographically, the increase in core sales was led by North America and Western Europe. Core sales in the business’ chemical
treatment solutions product line increased during the three-month period as a result of increased core sales across most major
end-markets. Geographically, the increase in core sales of chemical treatment solutions was driven by North America.
Core sales in the segment’s product identification businesses increased at a low-single digit rate during the three-month period
ended March 31, 2023, compared to the comparable period of 2022. Core sales in the marking and coding business were
essentially flat during the three-month period as increased demand in the food and beverage end-market was offset by lower
demand in the consumer packaging end-market. Geographically, increased core sales in Western Europe were offset by lower
core sales in North America and Russia. For the packaging and color solutions products and services, core sales increased in
the three-month period, geographically led by North America and Western Europe.
In September 2022, the Company announced its intention to separate its Environmental & Applied Solutions business into a
publicly traded company, to be known as Veralto Corporation. The Environmental & Applied Solutions business had sales for
the year ended December 31, 2022 of approximately $4.8 billion. The transaction is expected to be tax-free to the Company’s
shareholders. The Company is targeting to complete the planned separation of the Environmental & Applied Solutions business
in the fourth quarter of 2023, subject to the satisfaction of certain conditions, including obtaining final approval from the
Danaher Board of Directors, satisfactory completion of financing, receipt of tax opinions, receipt of favorable rulings from the
Internal Revenue Services (“IRS”) and receipt of other regulatory approvals. Until the completion of the planned separation,
the Environmental & Applied Solutions business will be reported as continuing operations.
Operating Profit Performance
Operating profit margins increased 420 basis points during the three-month period ended March 31, 2023 as compared to the
comparable period of 2022. The following factors favorably impacted year-over-year operating profit margin:
• Higher first quarter 2023 core sales and incremental year-over-year cost savings associated with restructuring and
continuing productivity improvement initiatives, net of incremental year-over-year costs associated with material,
transportation and labor initiatives and sales and marketing growth initiatives - 395 basis points
• The incremental net accretive effect in 2023 of acquired businesses - 15 basis points
• First quarter 2022 impairments of accounts receivable and inventory in Russia - 10 basis points
COST OF SALES AND GROSS PROFIT
Three-Month Period Ended
($ in millions) March 31, 2023 April 1, 2022
Sales $ 7,167 $ 7,688
Cost of sales (2,797) (2,983)
Gross profit $ 4,370 $ 4,705
Gross profit margin 61.0 % 61.2 %
The year-over-year decrease in cost of sales during the three-month period ended March 31, 2023 as compared to the
comparable period in 2022, was due primarily to the impact of lower year-over-year sales volumes.
Year-over-year gross profit margin decreased during the three-month period ended March 31, 2023 as compared to the
comparable period in 2022 due primarily to lower core sales and the impact of product mix.
Table of Contents
30

-- 33 of 42 --

OPERATING EXPENSES
Three-Month Period Ended
($ in millions) March 31, 2023 April 1, 2022
Sales $ 7,167 $ 7,688
Selling, general and administrative (“SG&A”) expenses 2,147 2,092
Research and development (“R&D”) expenses 429 441
SG&A as a % of sales 30.0 % 27.2 %
R&D as a % of sales 6.0 % 5.7 %
SG&A expenses as a percentage of sales increased for the three-month period ended March 31, 2023 as compared to the
comparable period in 2022, driven primarily by the impact of decreased leverage of the Company’s general and administrative
cost base, including amortization expense, resulting from lower 2023 sales, as well as costs incurred related to preparation for
the anticipated separation of the Company’s Environmental & Applied Solutions business, continued investments in sales and
marketing growth initiatives and increased labor costs.
R&D expenses (consisting principally of internal and contract engineering personnel costs) as a percentage of sales increased
during the three-month period ended March 31, 2023 as compared to the comparable period of 2022, primarily due to the year-
over-year sales decline and the timing of new product development initiatives.
OTHER INCOME (EXPENSE), NET
For a description of the Company’s other income (expense), net during the three-month periods ended March 31, 2023 and
April 1, 2022, refer to Note 7 to the accompanying Consolidated Condensed Financial Statements.
INTEREST COSTS AND FINANCING
For a discussion of the Company’s outstanding indebtedness, refer to Note 10 to the accompanying Consolidated Condensed
Financial Statements.
Interest expense of $68 million for the three-month period ended March 31, 2023, was $14 million higher than the comparable
period of 2022, due primarily to higher average interest rates on the Company’s outstanding Euro-denominated commercial
paper borrowings in the three-month period in 2023 versus the comparable period of 2022. For a discussion of the Company’s
cross-currency swap derivative contracts, refer to Note 11 to the accompanying Consolidated Condensed Financial Statements.
Interest income of $48 million for the three-month period ended March 31, 2023 was $47 million higher than the comparable
period of 2022, due primarily to higher average interest rates and higher average cash balances in 2023 compared to 2022.
INCOME TAXES
The following table summarizes the Company’s effective tax rate:
Three-Month Period Ended
March 31, 2023 April 1, 2022
Effective tax rate 19.4 % 17.8 %
The Company operates globally, including in certain jurisdictions with lower tax rates than the U.S. federal statutory rate.
Therefore, the impact of operating in such jurisdictions contributes to a lower effective tax rate compared to the U.S. federal
statutory tax rate.
The effective tax rate for the three-month period ended March 31, 2023 differs from the U.S. federal statutory rate of 21.0%
principally due the geographic mix of earnings described above and net discrete benefits of $5 million related primarily to
excess tax benefits from stock-based compensation and the release of reserves for uncertain tax positions due to the expiration
of statutes of limitation, partially offset by tax costs related to the planned separation of the Environmental & Applied Solutions
business and changes in estimates associated with prior period uncertain tax positions. The net discrete benefits reduced the
effective tax rate by 0.3% for the three-month period ended March 31, 2023.
The effective tax rate for the three-month period ended April 1, 2022 differs from the U.S. federal statutory rate of 21.0%
principally due to net discrete benefits of $41 million related primarily to excess tax benefits from stock-based compensation
and changes in estimates associated with prior period uncertain tax positions. These factors reduced the effective tax rate by
2.0% for the three-month period ended April 1, 2022.
Table of Contents
31

-- 34 of 42 --

The Company conducts business globally, and files numerous consolidated and separate income tax returns in federal, state and
foreign jurisdictions. In addition to the Company’s significant presence in the U.S., the Company also has a significant
presence in China, Denmark, Germany, Singapore, Sweden, Switzerland and the United Kingdom (“UK”). Excluding these
jurisdictions, the Company believes that a change in the statutory tax rate of any individual foreign country would not have a
material impact on the Company’s financial statements given the geographical dispersion of the Company’s taxable income.
The Company and its subsidiaries are routinely examined by various domestic and international taxing authorities. The IRS has
completed the examinations of substantially all of the Company’s federal income tax returns through 2015 and is currently
examining certain of the Company’s federal income tax returns for 2016 through 2018. In addition, the Company has
subsidiaries in Belgium, Canada, China, Denmark, France, Germany, India, Italy, Japan, Korea, Switzerland, the UK and
various other countries, states and provinces that are currently under audit for years ranging from 2004 through 2021.
In the fourth quarter of 2022, the IRS proposed significant adjustments to the Company’s taxable income for the years 2016
through 2018 with respect to the deferral of tax on certain premium income related to the Company’s self-insurance programs.
For income tax purposes, the recognition of premium income has been deferred in accordance with U.S. tax laws related to
insurance. The IRS challenged the deferral of premium income for certain types of the Company’s self-insurance policies. The
proposed adjustments would have increased the Company’s taxable income over the 2016 through 2018 periods by
approximately $2.5 billion. In the first quarter of 2023, the Company settled these proposed adjustments with the IRS, although
the audit is still open with respect to other matters for the 2016 through 2018 period. The impact of the settlement with respect
to the Company’s self-insurance policies was not material to the Company’s financial statements, including cash flows and the
effective tax rate. As the settlement with the IRS was specific to the audit period, the settlement does not preclude the IRS from
proposing similar adjustments to the Company’s self-insurance programs with respect to periods subsequent to 2018.
Management believes the positions the Company has taken in its U.S. tax returns are in accordance with the relevant tax laws.
The Company expects its effective tax rate for the remainder of 2023 to be approximately 19.5%. The Company’s effective tax
rate could vary as a result of many factors, including but not limited to the following:
• The expected rate for the remainder of 2023 includes the anticipated discrete income tax benefits from excess tax
deductions related to the Company’s stock compensation programs, which are reflected as a reduction in tax expense,
though the actual benefits (if any) will depend on the Company’s stock price and stock option exercise patterns.
• The actual mix of earnings by jurisdiction could fluctuate from the Company’s projection.
• The tax effects of other discrete items, including accruals related to tax contingencies, the resolution of worldwide tax
matters, tax audit settlements, statute of limitations expirations and changes in tax regulations.
• Any future changes in tax law or the implementation of recently proposed increases in tax rates, the impact of future
regulations and any related additional tax planning efforts to address these changes.
As a result of the uncertainty in predicting these items, it is reasonably possible that the actual effective tax rate used for
financial reporting purposes will change in future periods.
Refer to Note 6 to the Consolidated Condensed Financial Statements for discussion regarding the Company’s significant tax
matters.
COMPREHENSIVE INCOME
In 2023, comprehensive income increased $180 million for the three-month period ended March 31, 2023 as compared to the
comparable period of 2022, primarily driven by income from foreign currency translation adjustments and income from cash
flow hedge adjustments, partially offset by lower net earnings in the year-over-year period. The Company recorded foreign
currency translation gains of $25 million and losses of $343 million for the three-month periods ended March 31, 2023 and
April 1, 2022, respectively. The Company recorded gains of $81 million from cash flow hedge adjustments related to the
Company’s cross-currency swap derivative contracts for the three-month period ended March 31, 2023 as compared to losses of
$20 million for the comparable period of 2022.
LIQUIDITY AND CAPITAL RESOURCES
Management assesses the Company’s liquidity in terms of its ability to generate cash to fund its operating, investing and
financing activities. The Company continues to generate substantial cash from operating activities and believes that its
operating cash flow, cash on hand and other sources of liquidity will be sufficient to allow it to continue investing in existing
businesses (including capital expenditures), consummating strategic acquisitions and investments, paying interest and servicing
Table of Contents
32

-- 35 of 42 --

debt, paying dividends, funding restructuring activities, repurchasing common stock and managing its capital structure on a
short-term and long-term basis.
The Company has relied primarily on borrowings under its commercial paper program to address liquidity requirements that
exceed the capacity provided by its operating cash flows and cash on hand, while also accessing the capital markets from time
to time including to secure financing for more significant acquisitions. Subject to any limitations that may result from market
disruptions, the Company anticipates following the same approach in the future.
Overview of Cash Flows and Liquidity
Following is an overview of the Company’s cash flows and liquidity ($ in millions):
Three-Month Period Ended
($ in millions) March 31, 2023 April 1, 2022
Total operating cash provided by operations $ 1,947 $ 1,968
Cash paid for acquisitions $ — $ (17)
Payments for additions to property, plant and equipment (275) (250)
Proceeds from sales of property, plant and equipment — 2
Payments for purchases of investments (43) (274)
Proceeds from sales of investments 1 17
All other investing activities 13 19
Total cash used in investing activities $ (304) $ (503)
Payments for the issuance of common stock in connection with stock-based
compensation, net $ (34) $ (46)
Payment of dividends (204) (191)
Net (repayments of) proceeds from borrowings (maturities of 90 days or less) (4) 10
All other financing activities (20) (47)
Total cash used in financing activities $ (262) $ (274)
• Operating cash flows decreased $21 million, or 1%, during the three-month period ended March 31, 2023 as compared
to the comparable period of 2022, as lower net earnings from continuing operations (after excluding in both periods
charges for depreciation, amortization, stock compensation and unrealized investment gains/losses) were partially
offset by lower cash used in aggregate for accounts receivables, inventories, trade accounts payable and prepaid and
accrued expenses, including deferred taxes, in 2023 compared to the prior year.
• Net cash used in investing activities consisted primarily of capital expenditures and investments and decreased year-
over-year primarily as a result of lower cash paid for acquisitions and investments in the 2023 period compared to
2022.
• As of March 31, 2023, the Company held approximately $7.4 billion of cash and cash equivalents.
Operating Activities
Cash flows from operating activities can fluctuate significantly from period-to-period as working capital needs and the timing
of payments for income taxes, restructuring activities and productivity improvement initiatives, pension funding and other items
impact reported cash flows.
Operating cash flows were approximately $1.9 billion for the first three months of 2023, a decrease of $21 million, or 1%, as
compared to the comparable period of 2022. The year-over-year change in operating cash flows from 2022 to 2023 was
primarily attributable to the following factors:
• 2023 operating cash flows reflected a decrease of $275 million in net earnings for the first three months of 2023 as
compared to the comparable period in 2022.
• Net earnings for the first three months of 2023 also reflected a decrease of $55 million of depreciation, intangible asset
amortization, stock compensation expense and unrealized investment gains/losses as compared to the comparable
period of 2022. Amortization expense primarily relates to the amortization of intangible assets. Depreciation expense
Table of Contents
33

-- 36 of 42 --

relates to the Company’s manufacturing and operating facilities as well as instrumentation leased to customers under
operating-type lease (“OTL”) arrangements. Depreciation, amortization and stock compensation are noncash expenses
that decrease earnings without a corresponding impact to operating cash flows. Unrealized investment gains/losses
impact net earnings without immediately impacting cash flows as the cash flow impact from investments occurs when
the invested capital is returned to the Company.
• The aggregate of trade accounts receivable, inventories and trade accounts payable provided $146 million in operating
cash flows during the first three months of 2023, compared to $482 million of operating cash flows used in the
comparable period of 2022. The amount of cash flow generated from or used by the aggregate of trade accounts
receivable, inventories and trade accounts payable depends upon how effectively the Company manages the cash
conversion cycle, which effectively represents the number of days that elapse from the day it pays for the purchase of
raw materials and components to the collection of cash from its customers and can be significantly impacted by the
timing of collections and payments in a period.
• The aggregate of prepaid expenses and other assets, deferred income taxes and accrued expenses and other liabilities
used $263 million of operating cash flows during the first three months of 2023, compared to $56 million of operating
cash flows provided in the comparable period of 2022. The timing of cash payments for various employee-related
liabilities, customer funding and changes in accrued expenses drove the majority of this change.
Investing Activities
Cash flows relating to investing activities consist primarily of cash used for acquisitions and capital expenditures, including
instruments leased to customers, cash used for investments and cash proceeds from divestitures of businesses or assets.
Net cash used in investing activities decreased approximately $199 million in the three-month period ended March 31, 2023
compared to the comparable period of 2022, primarily as a result of a decrease in cash used for the purchase of investments. In
the first three months of 2023 and 2022, the Company invested $43 million and $274 million, respectively, in non-marketable
equity securities and partnerships.
Capital expenditures are made primarily for increasing manufacturing capacity, replacing equipment, supporting new product
development, improving information technology systems and the manufacture of instruments that are used in OTL
arrangements that certain of the Company’s businesses enter into with customers. Capital expenditures decreased $25 million
on a year-over-year basis for the three-month period ended March 31, 2023 compared to the comparable period in 2022. For
the full year 2023, the Company forecasts capital spending to be approximately $1.5 billion, driven primarily by continued
expenditures to support customer demand.
Financing Activities and Indebtedness
Cash flows relating to financing activities may consist of cash flows associated with the issuance and repayments of
commercial paper, issuance and repayment of long-term debt, borrowings under committed credit facilities, issuance and
repurchases of common stock, issuance of preferred stock and payments of cash dividends to shareholders. Financing activities
used cash of $262 million during the three-month period ended March 31, 2023 compared to $274 million of cash used in the
comparable period of 2022. The year-over-year decrease in cash used by financing activities was due to lower payments related
to the issuance of common stock and lower all other financing activities, partially offset by higher payments of dividends and
net repayment of borrowings in 2023.
For a description of the Company’s outstanding debt as of March 31, 2023 and the Company’s commercial paper programs and
credit facility, refer to Note 10 to the accompanying Consolidated Condensed Financial Statements. As of March 31, 2023, the
Company was in compliance with all of its respective debt covenants.
As discussed in Note 14 in the accompanying Consolidated Condensed Financial Statements all outstanding shares of the
Company’s 4.75% MCPS Series A and 5.00% MCPS Series B converted to common shares on April 15, 2022 and April 17,
2023, respectively. The Company’s 4.75% MCPS Series A converted to common shares at a rate of 6.6632 common shares per
share of preferred stock. The Company’s 5.00% MCPS Series B converted to common shares at a rate of 5.0175 common
shares per share of preferred stock.
Stock Repurchase Program
For information regarding the Company’s stock repurchase program, refer to Part II—Item 2, “Unregistered Sales of Equity
Securities and Use of Proceeds”.
Table of Contents
34

-- 37 of 42 --

Dividends
Aggregate cash payments for dividends on Company common stock during the three-month period ended March 31, 2023 were
$182 million and aggregate cash payments for dividends on the Company’s MCPS during the three-month period ended
March 31, 2023 were $22 million. The increase in dividend payments for common stock over the comparable period of 2022
primarily relates to the increase in the quarterly dividend rate for common stock beginning with respect to the dividend paid in
the second quarter of 2022. The decrease in MCPS dividend payments compared to the comparable period of 2022 primarily
relates to the conversion of all outstanding shares of the Company’s 4.75% MCPS Series A to common shares on April 15,
2022.
In the first quarter of 2023, the Company declared a regular quarterly dividend of $0.27 per share of Company common stock
payable on April 28, 2023 to holders of record as of March 31, 2023. In addition, the Company declared a quarterly cash
dividend of $12.50 per MCPS Series B that was paid on April 17, 2023 to holders of record as of March 31, 2023.
Cash and Cash Requirements
As of March 31, 2023, the Company held approximately $7.4 billion of cash and cash equivalents that were held on deposit
with financial institutions or invested in highly liquid investment-grade debt instruments with a maturity of 90 days or less. Of
the cash and cash equivalents, approximately $3.7 billion was held within the United States and approximately $3.7 billion was
held outside of the United States. The Company will continue to have cash requirements to support general corporate purposes,
which may include working capital needs, capital expenditures, acquisitions and investments, paying interest and servicing
debt, paying taxes and any related interest or penalties, funding its restructuring activities and pension plans as required, paying
dividends to shareholders, repurchasing shares of the Company’s common stock and supporting other business needs.
The Company generally intends to use available cash and internally generated funds to meet these cash requirements, but in the
event that additional liquidity is required, the Company may also borrow under its commercial paper programs (if available) or
borrow under the Company’s Five-Year Facility, enter into new credit facilities and either borrow directly thereunder or use
such credit facilities to backstop additional borrowing capacity under its commercial paper programs (if available) and/or access
the capital markets (if available). The Company also may from time to time seek to access the capital markets to take
advantage of favorable interest rate environments or other market conditions. With respect to the commercial paper and other
notes scheduled to mature during the remainder of 2023, the Company expects to repay the principal amounts when due using
available cash, proceeds from new issuances of commercial paper (if available), drawing on its Five-Year Facility and/or
proceeds from other debt issuances.
While repatriation of some cash held outside the United States may be restricted by local laws, most of the Company’s foreign
cash could be repatriated to the United States. Following enactment of the Tax Cuts and Jobs Act and the associated Transition
Tax, in general, repatriation of cash to the United States can be completed with no incremental U.S. tax; however, repatriation
of cash could subject the Company to non-U.S. taxes on distributions. The cash that the Company’s non-U.S. subsidiaries hold
for indefinite reinvestment is generally used to finance foreign operations and investments, including acquisitions. The income
taxes, if any, applicable to such earnings including basis differences in our foreign subsidiaries are not readily determinable. As
of March 31, 2023, management believes that it has sufficient sources of liquidity to satisfy its cash needs, including its cash
needs in the United States.
During 2023, the Company’s cash contribution requirements for its U.S. and non-U.S. defined benefit pension plans are
forecasted to be approximately $10 million and $37 million, respectively. The ultimate amounts to be contributed depend upon,
among other things, legal requirements, underlying asset returns, the plan’s funded status, the anticipated tax deductibility of
the contribution, local practices, market conditions, interest rates and other factors.
CRITICAL ACCOUNTING ESTIMATES
There have been no material changes to the Company’s critical accounting estimates as described in the 2022 Annual Report.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Quantitative and qualitative disclosures about market risk appear in “Management’s Discussion and Analysis of Financial
Condition and Results of Operations—Financial Instruments and Risk Management,” in the Company’s 2022 Annual Report.
There were no material changes during the quarter ended March 31, 2023 to this information as reported in the Company’s
2022 Annual Report.
Table of Contents
35

-- 38 of 42 --

ITEM 4. CONTROLS AND PROCEDURES
The Company’s management, with the participation of the Company’s President and Chief Executive Officer, and Executive
Vice President and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and
procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended
(the “Exchange Act”)) as of the end of the period covered by this report. Based on such evaluation, the Company’s President
and Chief Executive Officer, and Executive Vice President and Chief Financial Officer, have concluded that, as of the end of
such period, the Company’s disclosure controls and procedures were effective.
Except as set forth below, there have been no changes in the Company’s internal control over financial reporting (as such term
is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the Company’s most recent
completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal
control over financial reporting.
In January 2023, the Company began integrating various business processes within its Biotechnology businesses, including the
transition of certain activities to one existing common enterprise resource planning system and to common applications used for
various financial reporting and operational purposes. In connection with this integration and related business process changes,
the Company replaced certain internal controls with new or modified controls. The integration is being executed in phases
throughout 2023 and is intended to support customer requirements and accommodate future business demands.
Table of Contents
36

-- 39 of 42 --

PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
For additional information regarding legal proceedings, refer to the section titled “Legal Proceedings” in the MD&A section of
the Company’s 2022 Annual Report.
ITEM 1A. RISK FACTORS
Information regarding risk factors can be found in “Management’s Discussion and Analysis of Financial Condition and Results
of Operations—Information Related to Forward-Looking Statements,” in Part I—Item 2 of this Form 10-Q and in Part I—Item
1A of Danaher’s 2022 Annual Report on Form 10-K.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Neither the Company nor any “affiliated purchaser” repurchased any shares of Company common stock during the three-month
period ended March 31, 2023. On July 16, 2013, the Company’s Board of Directors approved a repurchase program (the
“Repurchase Program”) authorizing the repurchase of up to 20 million shares of the Company’s common stock from time to
time on the open market or in privately negotiated transactions. As of March 31, 2023, approximately 20 million shares
remained available for repurchase pursuant to the Repurchase Program. There is no expiration date for the Repurchase
Program, and the timing and amount of any future shares repurchased under the program will be determined by members of the
Company’s management based on its evaluation of market conditions and other factors. The Repurchase Program may be
suspended or discontinued at any time. Any repurchased shares will be available for use in connection with the Company’s
equity compensation plans (or any successor plans) and for other corporate purposes. The Company expects to fund any future
stock repurchases using the Company’s available cash balances or proceeds from the issuance of debt.
ITEM 5. OTHER INFORMATION
Disclosure Pursuant to Section 13(r) of the Exchange Act
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012, which amended the Exchange Act
to add Section 13(r) thereof, an issuer is required to disclose in its annual or quarterly reports, as applicable, whether, during the
relevant reporting period, it or any entity acting on its behalf knowingly engaged in certain activities, transactions or dealings
related to parties subject to sanctions administered by the Office of Foreign Assets Control (“OFAC”) within the U.S.
Department of the Treasury, even if those transactions are authorized by law.
On March 2, 2021, the U.S. government designated the Russian Federal Security Service (the “FSB”) as a blocked party under
Executive Order 13382. On the same day, the U.S. Department of the Treasury’s Office of Foreign Assets Control issued
General License No. 1B (the “OFAC General License”), which generally authorizes U.S. companies to engage in certain
transactions and dealings with the FSB necessary and ordinarily incident to requesting or obtaining licenses, permits,
certifications or notifications issued or registered by the FSB for the importation, distribution or use of information technology
products in Russia. Section 13(r) of the Exchange Act now requires disclosure of dealings with FSB, even where the activities
were conducted in compliance with applicable laws and regulations.
In the normal course of business, as permitted and authorized by the OFAC General License (but subject to the Company’s
suspension of sales prohibited by sanctions and suspension of certain other product shipments to Russia as a result of the
conflict with Ukraine), certain of the Company’s subsidiaries from time to time file notifications with, or apply for import
licenses and permits from, the FSB as required pursuant to Russian encryption product import controls for the purpose of
enabling such subsidiaries or their channel partners to import and distribute certain products in the Russian Federation. There
are no gross revenues or net profits directly associated with these activities, and neither the Company nor any of its subsidiaries
distribute or sell products or provide services to the FSB.
Table of Contents
37

-- 40 of 42 --

ITEM 6. EXHIBITS
(a) Exhibits:
3.1 Restated Certificate of Incorporation of Danaher Corporation (incorporated by reference from Exhibit 3.1 to
Danaher Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 29, 2012)
3.2
Certificate of Designations of the 5.00% Mandatory Convertible Preferred Stock, Series B, filed with the Secretary
of State of the State of Delaware on May 11, 2020 (incorporated by reference from Exhibit 3.1 to Danaher
Corporation’s Current Report on Form 8-K filed May 12, 2020)
3.3 Amended and Restated By-laws of Danaher Corporation (incorporated by reference from Exhibit 3.1 to Danaher
Corporation’s Current Report on Form 8-K filed December 7, 2022)
10.1 Danaher Corporation Excess Contribution Program, a sub-plan under the 2007 Omnibus Incentive Plan, as
amended and restated*
10.2 Amended and Restated Danaher Corporation Deferred Compensation Plan*
10.3 Amended and Restated Danaher Corporation & Subsidiaries Executive Deferred Incentive Program*
22.1 Subsidiary guarantors and issuers of guaranteed securities and affiliates whose securities collateralize securities of
the Registrant
31.1 Certification of Chief Executive Officer Pursuant to Item 601(b)(31) of Regulation S-K, As Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
31.2 Certification of Chief Financial Officer Pursuant to Item 601(b)(31) of Regulation S-K, As Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
32.1 Certification of Chief Executive Officer, Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906
of the Sarbanes-Oxley Act of 2002
32.2 Certification of Chief Financial Officer, Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906
of the Sarbanes-Oxley Act of 2002
101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its
XBRL tags are embedded within the Inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
* Indicates management contract or compensatory plan, contract or arrangement.
Table of Contents
38

-- 41 of 42 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
DANAHER CORPORATION
Date: April 24, 2023 By: /s/ Matthew R. McGrew
Matthew R. McGrew
Executive Vice President and Chief Financial Officer
Date: April 24, 2023 By: /s/ Christopher M. Bouda
Christopher M. Bouda
Vice President and Chief Accounting Officer
Table of Contents
39

-- 42 of 42 --